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Artesunate (ART) is an anti-malaria drug that has been shown to 
exhibit anti-tumor activity. Autophagy is an evolutionarily conserved process 
that degrades cytoplasmic proteins and organelles via the lysosomes. The 
effect of ART on autophagy is controversial. Moreover, whether autophagy is 
involved in ART-induced cell death has not been investigated. In addition, 
lysosomes have been shown to be required for ART-induced cell death while 
the mechanisms remain largely elusive. Therefore, we hypothesize that ART 
promotes cell death via regulating lysosomal functions. To test this hypothesis, 
we aimed to (i) examine the effects of ART on autophagy and lysosomes; (ii) 
investigate the implication of lysosomes and the underlying molecular 
mechanism in ART-mediated cell death. 
In the first part of our study, we showed that ART induced autophagy 
in human cervical cancer HeLa cells evidenced by the increase of autophagic 
flux. In the search of the mechanisms for ART-induced autophagy, we found 
that ART inhibits mechanistic/mammalian target of rapamycin complex 1 
(mTORC1) activity. To further explore the effect of ART on mTOR, we 
utilized tuberous sclerosis complex 2 (Tsc2)+/+ mouse embryonic fibroblasts 
(MEFs) and Tsc2-/- MEFs and found that mTORC1 activity was not impaired 
in Tsc2-/- MEFs, indicating that ART may inhibit mTORC1 via the class I 
PI3K-Akt-Tsc pathway. Interestingly, ART was found to be dominantly 
accumulated in the lysosomes and able to activate lysosomal function. 
Moreover, the activation of lysosomal function by ART was found to be 




In the second part of our study, we first confirmed the earlier findings 
that ART induces apoptotic cell death in cancer cells. We also found that 
lysosomes function upstream of mitochondria in reactive oxygen species 
(ROS) production, as the lysosomal inhibitor, bafilomycin A1 (BAF), was 
able to inhibit ART-induced mitochondrial ROS production. Importantly, we 
provided evidence that lysosomal iron is required for the lysosomal activation 
and mitochondrial ROS production induced by ART. Consistently, ART-
induced cell death is fully protected by lysosomal iron chelator deferoxamine 
mesylate (DFO) and BAF. Finally, we showed that ART-induced cell death is 
mediated by the release of iron in the lysosomes, which is resulted from the 
lysosomal degradation of ferritin, an iron storage protein. Meanwhile, over-
expression of ferritin heavy chain (FTH) significantly protects cells from 
ART-induced cell death. In addition, knockdown of nuclear receptor 
coactivator 4 (NCOA4), the adaptor protein for ferritin degradation, is able to 
rescue the ART-induced lysosome activation as well as cell death. 
In summary, our results demonstrate that ART induces autophagy via 
inhibition of mTORC1 activity and activation of lysosomal function. 
Degradation of ferritin in the lysosomes is required for ART-induced 
lysosomal activation as well as cell death, via a sequence of events including 
release of iron and enhanced ROS production from mitochondria. Thus, our 
study clarifies the effect of ART on autophagy and reveals a new mechanistic 
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1.1.1 Overview of artemisinin and artesunate 
Artemisinin, an active ingredient of a traditional Chinese medicinal 
plant Artemisia annua L. (qinhao), has been widely used for treatment of fever 
and chills caused by malaria infections (Klayman, 1985). Artesunate (ART), a 
water soluble derivate of artemisinin, was found to be one of the most 
effective and safe drugs for treatment of malaria (Sinclair et al., 2011). There 
are also several other derivatives of artemisinin including artemether, arteether 
and dihydroartemisinin (DHA) are also wildly used as anti-malaria drugs. The 
endoperoxide bridges of artemisinins are believed to be responsible for the 
mechanism of action. The successful identification of artemisinin and 
development of ART as the first-line drug for treatment of malaria has made a 
huge contribution to the control of this deadly disease, especially in some of 






Figure 1.1 Molecular structures of artemisinin and its main 
derivatives. 
 
1.1.2 Pharmacological effects of ART 
In addition to the anti-malaria function, ART has been found to possess 
a wide spectrum of pharmacological activities, including anti-cancer 
(Chaturvedi et al., 2010; Efferth, 2006), anti-viral (Efferth et al., 2008), anti-
inflammatory (Wang et al., 2007; Xu et al., 2007), anti-allergic and asthmatic 
activities (Cheng et al., 2011). There are continuous efforts and increasing 
interests in uncovering the underlying mechanisms of the above functions. 
 
1.1.2.1 Anti-malaria  
As shown in Figure 1.1, the basic structure of artemisinin and its 
monomers including ART is a sesquiterpene lactone. All of them contain an 
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endoperoxide bridge which is believed to be essential for its anti-malarial 
activity (Krishna et al., 2004). It is also widely accepted that cleavage of the 
endoperoxide bridge of artemisinins by ferrous iron results in carbon-centered 
free radicals production, which is essential for their anti-malarial activity 
(Eckstein-Ludwig et al., 2003; Klonis et al., 2013). The underlying 
mechanisms of the anti-malaria function of artemisinins have been extensively 
studied, including: (i) inhibition the PfATP6 of Plasmodium falciparum in 
Xenopus oocytes, the orthologue of mammalian SERCA (sarco/endoplasmic 
reticulum Ca2+-ATPase) (Eckstein-Ludwig et al., 2003); (ii) alkylation of 
cytosolic proteins such as translationally controlled tumor protein (PfTCTP) 
(Meshnick, 2002); (iii) interference with the heme and alkylation of heme 
(Cazelles et al., 2002), (iv) disruption of digestive vacuole membrane (del 
Pilar Crespo et al., 2008). Currently, chemical modifications and the 
development of multimeric artemisinin conjugates have led to the improved 
efficacies as well as the decreased adverse effects of the drugs (Ho et al., 
2014). 
  
1.1.2.2 Anti-inflammatory  
In the early 1980s, a water soluble derivative of artemisinin, 
hemisuccinate NA, was shown to possess immunosuppressive action against 
mitogen-stimulated mouse spleen cells and human peripheral lymphocytes 
(Shen et al., 1984). At present, there is increasing evidence to support the anti-
inflammation function of artemisinin and its derivatives, mainly in the 
following models: rheumatoid arthritis, allergic anaphylaxis; systemic lupus 
erythematosus and sepsis (Ho et al., 2014). Besides, ART has been shown to 
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possess anti-inflammatory effects in experimental colitis and Alzheimer's 
disease model (Shi et al., 2013; Yang et al., 2012).  
One of the most well studied mechanisms of the anti-inflammation 
function of artemisinins is via inhibition of the nuclear factor kappa B (NF-κB) 
signaling pathway (Li et al., 2006; Li et al., 2013). NF-κB has been shown to 
play a key role in inflammatory and immune responses via the regulation of 
genes encoding pro-inflammatory cytokines, chemokines, adhesion molecules 
and etc (Tak and Firestein, 2001; Xu et al., 2007; Yamamoto and Gaynor, 
2001). Therefore, inactivation of NF-κB leads to the repression of production 
of key proinflammatory cytokines of such as TNF-α, IL-1, IL-6, IL-12, 
reduction of the expression of enzymes such as nitric oxide synthase and 
inhibition of the activation of immunocompetent cells (Lawrence et al., 2001). 
It has been suggested that ART is capable of suppressing TNF-α induced 
production of IL-1, IL-6 and IL-8 via inhibiting NF-κB signal pathway in 
human rheumatoid arthritis fibroblast-like synoviocytes without affecting the 
phosphorylation of mitogen-activated protein kinase (MAPK), extracellular 
regulated kinases (ERK) and Jun N-terminal kinases (JNK) (Xu et al., 2007). 
Moreover, a recent study showed that ART has the inhibitory effect on 
collagen-induced arthritis through NF-κB and MAPK signaling pathway in 
rats (Li et al., 2013).  
The anti-inflammation effects of ART have also been shown to be 
involved in the inhibition of the phosphoinositide 3- kinase (PI3K)-Akt 
signaling pathway and activation of the NF-E2-related factor 2 
(Nrf2)/antioxidant responsive element (ARE) pathway (Cheng et al., 2011; Ho 
et al., 2012; Lee et al., 2012; Xu et al., 2007). Because of the key role of PI3K-
6 
 
Akt signaling pathway in the activation and immune responses of eosinophils, 
T and B lymphocytes, and mast cells, Cheng et al. investigated the anti-
inflammatory effect of ART in ovalbumin (OVA)-induced inflammatory mice 
as well as in house dust mite induced mouse asthma model (Cheng et al., 
2011). They found that ART inhibited the OVA-induced phosphorylation of 
Akt. They further made use of primary human bronchial epithelial cells and 
found that EGF-induced PI3K-Akt activation is also inhibited by ART 
treatment. Later on, the same group found that ART significantly enhanced 
nuclear Nrf2 protein level in lung tissues from OVA-challenged mice and in 
TNF-α-stimulated human bronchial epithelial cells (Ho et al., 2012). In 
addition, the activation of Nrf2 pathway by ART treatment has been shown in 
an ERK-dependent manner in microglial BV2 cells (Lee et al., 2012).  
 
1.1.2.3 Anti-viral  
The anti-viral functions of ART were mainly demonstrated in Herpes 
viruses as well as Hepatitis B and C viruses (Efferth et al., 2008; Ho et al., 
2014). ART with a concentration of 15 μM inhibits more than 80% of the 
DNA replication in human cytomegalovirus (HCMV) and herpes simplex 
virus type 1 (HSV-1) in vitro (Efferth et al., 2002; Efferth et al., 2008). 
Shapira et al. first reported that oral treatment with ART (100 mg/day) 
reduced the viral load (1.7–2.1 log reduction) and improved hematopoiesis in 
a 12-year-old patient within 10 days who suffered from late drug-resistant 
HCMV infection after receiving haploidentical T cell–depleted hematopoietic 
stem cells from his father (Shapira et al., 2008). It has been shown that co-
treatment with ferrous iron on HCMV-infected ﬁbroblasts enhanced the 
antiviral effect of ART, which is similar to the findings that ferrous iron is 
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required for the anti-malaria function (Kaptein et al., 2006). One of the 
possible mechanisms underlying its anti-HCMV function is that ART inhibits 
the PI3K pathway and thus diminishes the activation of NF-κB and Sp1, 
which is linked to the replication of HCMV (Efferth et al., 2002).  
The anti-hepatitis B virus (HBV) activity was first reported by Romero et 
al. They found that ART was able to suppress HBV surface antigen (HBsAg) 
secretion and reduce HBV-DNA levels in HepG2 2.2.15 cells (Romero et al., 
2005). The dose of ART was similar to its activity against HCMV, which is 
less than 10 μM (Efferth et al., 2002). Although the effect is weaker than that 
of lamivudine, a widely used inhibitor for chronic hepatitis B, a synergic 
inhibitory effect in HBsAg release has been shown by the combined treatment 
of ART and lamivudine (20 nM each) without inducing toxicity in host cells 
(Romero et al., 2005). However, at present the underlying mechanisms of its 
anti-HBV activity are not clear and need to be further investigated. 
Artemisinin has been reported to inhibit HCV replication, with an EC50 
(50% effective concentration) about 78 μM without affecting the proliferation 
of Huh5-2 cells (Paeshuyse et al., 2006). Moreover, the anti-HCV activity of 
artemisinin was enhanced 5-fold by combination with hemin, an iron donor, 
without observing cytotoxic effect (Paeshuyse et al., 2006).  
 
1.1.2.4 Anti-cancer  
The anti-cancer effect of artemisinin was first described in 1993, in which 
the researchers showed that the artemisinin as well as its derivatives such as 
ART and dihydroartemisinin exhibits toxicity to Ehrlich ascites tumor (EAT) 
cells (Woerdenbag et al., 1993). At present, there is extensive evidence 
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suggesting the anti-cancer function of artemisinins, especially ART and DHA 
(Ho et al., 2014). Here we focus on the anti-cancer function of ART. Up to 
date, the anti-cancer function of ART is mainly based on the following 
observations: (i) induction of cell cycle arrest (Longxi et al., 2011; Zhao et al., 
2011), (ii) induction of cell death and sensitization to tumor necrosis factor-
related apoptosis-inducing ligand (TRAIL)-induced apoptosis (He et al., 2010; 
Thanaketpaisarn et al., 2011), (iii) inhibition of angiogenesis (Chen et al., 
2004; Dell'Eva et al., 2004), (iv) reduction of cell invasion and metastasis 
(Rasheed et al., 2010). These anti-cancer effects of ART are summarized in 
Figure 1.2 as below. Moreover, the anti-cancer potential of ART has also been 
tested in animal models. Currently there is one clinical trial ongoing using 
ART in metastatic breast cancer 
(http://clinicaltrials.gov/ct2/show/NCT00764036) and the results are still 
pending.  
 





(i) Arrest of cell cycle and inhibition of cell proliferation 
One hallmark of cancer is its sustaining proliferative signaling (Hanahan 
and Weinberg, 2011). There are a number of studies showing the cell cycle 
arrest and anti-proliferation effect of ART in both in vitro and in vivo models 
(Longxi et al., 2011; Zhao et al., 2011; Du et al., 2010; Li et al., 2007). 
Notably, the effect of ART on different phases of cell cycle may be different. 
Longxi et al. showed that ART induces G1 phase cycle arrest via up-
regulating the p53 expression level in rat primary hepatic stellate cells (Longxi 
et al., 2011). Meanwhile, Zhao et al. showed that ART treatment leads to 
G2/M phase cell cycle arrest and growth inhibition of human non-small cell 
lung cancer A549 cells via increasing nitrogen oxide (NO) production (Zhao 
et al., 2011). In a very recent study, ART was found to induce G2/M cell cycle 
arrest via induction of autophagy in MCF-7 and MDA-MB-231 breast cancer 
cells (Chen et al., 2014).  
 
(ii) Induction of cell death  
Three types of cell death have been defined: type-I cell death or 
apoptosis, type-II cell death or autophagic cell death, and type-III cell death, 
or necrosis (Clarke, 1990). Type-I cell death or apoptosis is characterized by 
activation of caspase, chromatin fragmentation, cytoplasmic blebbing and 
phagocyte engulfment of the apoptotic cell such that complete degradation of 
the cell requires the engulfing cell’s lysosomal machinery (Clarke, 1990; Kerr, 
1972). Type-III cell death, or necrosis, is characterized by swelling and abrupt 
rupture of plasma membrane. Type-II cell death or autophagic cell death refers 
to the cell death that autophagy is the only mechanism that involves in 
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executing the cell death without any signature of apoptosis or necrosis, which 
will be discussed in detail later (Scarlatti et al., 2009). 
Generally, there are two main pathways initiating apoptosis: the 
extrinsic death pathway which initiates by binding of death receptor ligands to 
speciﬁc death receptors on the cell surface and the intrinsic pathway which 
initiates at the mitochondrial level (Schulze-Bergkamen and Krammer, 2004). 
ART has been shown to induce apoptosis via intrinsic pathway evidenced by 
the release of cytochrome c and activation of caspase-9 and caspase-3 in 
leukemic T cell lines and human osteosarcoma HOS cell (Efferth et al., 2007; 
Xu et al., 2011). Furthermore, ART-induced mitochondrial apoptosis is 
dependent on iron in human breast cancer cells (Hamacher-Brady et al., 2011). 
In addition to apoptosis, ART has been shown to induce necrosis in human 
glioblastoma cells (LN-229) (Berdelle et al., 2011) and oncosis-like cell death 
in human pancreatic cancer cells (Du et al., 2010). 
In addition, ART was also found to be able to sensitize to TRAIL-induced 
apoptosis in cervical cancer cells (Thanaketpaisarn et al., 2011). The study 
also suggested the sensitization effect of ART is due to its suppressive effect 
on NF-kB activation induced by TRAIL (Thanaketpaisarn et al., 2011). Table 
1.1 summarizes the findings on ART-induced cell death in different cancer 





Table 1.1 Anti-cancer potential of ART tested in vitro 
 
Cancer cells Dose (µM) Duration Outcomes References  
Human leukemic T 
cells (CCRF-CEM, 
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(iii) Inhibition of angiogenesis 
Angiogenesis is a process of new blood vessels formation that plays an 
important role in the tumor growth and metastasis (Chung and Ferrara, 2011). 
When a tumor reaches to a certain size, angiogenesis will be triggered by 
hypoxia and nutrient deprivation (Folkman and Hanahan, 1991). Therefore, 
inhibition of tumor-related angiogenesis has been considered as an important 
approach of cancer therapy (Weis and Cheresh, 2011). The first report on the 
inhibitory effect of ART on angiogenesis is published in human umbilical vein 
endothelial cell (Chen et al., 2003). Subsequently, Raffaella and his colleagues 
found that ART strongly inhibits angiogenesis in vivo by using the Matrigel 
plug assay (Dell'Eva et al., 2004). With regards to the mechanism of the 
antiangiogenic effect induced by ART, it has been suggested that ART reduces 
the production of vascular endothelial growth factor (VEGF), one of the most 
potent angiogenic factors, in human umbilical vein endothelial cells and 
chronic myeloid leukemia K562 cells (Chen et al., 2004; Zhou et al., 2007). 
Recent studies also showed that ART inhibits angiogenesis via induction of 
iron/ROS-dependent apoptosis in vascular endothelial cells (Cheng et al., 
2013). 
 
(iv) Reduction of cell invasion and metastasis  
The inhibitory effect of ART on invasion and metastasis are less reported 
and there is only one report showing that ART attenuates invasion and 
metastasis by targeting the essential extracellular proteases, including type IV 
collagenase (MMP-2) and matrilysin (MMP-7) in non-small cell lung cancer 
(Rasheed et al., 2010). 
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(v) Suppression of tumor growth 
The anti-cancer effect of ART has also been tested in animal models as 
summarized in Table 1.2. These studies clearly demonstrate that ART is able 
to suppress tumor growth without observable side effects in vivo.  
 
Table 1.2 Anti-cancer potential of ART tested in vivo 
 
Models Treatment Outcomes References 
Nude male mice, 




30 mg/kg/day of 
ART in combination 












mice, xenografts with 
human osteosarcoma 
HOS cell line 
50, 100, or 200 
mg/kg ART once 










    
Female BALB/c 




25, 50, or 100 














Female athymic nude 
mice, xenografts with 
colorectal cancer cell 
line 
100 mg/kg every 
day for 20 days, or 
300 mg/kg every 3 









    
Female athymic nude 




50, 100 mg/kg/day, 

















1.1.3 Molecular mechanisms underlying ART-mediated cell death in 
cancer cells  
1.1.3.1 Induction of oxidative stress 
Oxidative stress refers to a disturbance in the pro-oxidant and 
antioxidant balance, which results in potential damage to cells by causing the 
breakage of DNA double stands, cross-linking of proteins and peroxidation of 
lipids (Chandra et al., 2000). It has been demonstrated to be involved in 
several physiological processes including cell proliferation, cell growth, cell 
survival and aging (Finkel and Holbrook, 2000; Sauer et al., 2001). Moreover, 
it has also been implicated in pathological processes such as cell death, DNA 
damage and in diseases such as cancer and neurodegenerative diseases 
(Klaunig and Kamendulis, 2004; Lin and Beal, 2006; Young and Woodside, 
2001).  
Reactive oxygen species (ROS) are usually divided into two groups: free 
radicals such as superoxide radicals (O2
.−) and non-radical ROS such as 
hydrogen peroxide (H2O2) (Dayem et al., 2010). ROS production can be 
triggered by external agents or be generated endogenously (Figure 1.3) (Finkel 
and Holbrook, 2000). Mitochondria are considered as the most important 
source of intracellular ROS production as the redox centres complex I (NADH 
dehydrogenase) and complex III (ubiquinone–cytochrome c reductase) in the 
electron transport chain may leak electrons to oxygen. The oxygen is then can 
be reduced to superoxide anion which is the precursor of most ROS (Turrens, 
2003). To prevent the oxidative damage caused by ROS, there are complicated 
antioxidant defenses including both antioxidant enzymatic systems and non-
enzymatic systems (Figure 1.3). Antioxidant enzymes may scavenge free 
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radicals by catalyzing them to non-toxic forms. For example, catalase, the first 
characterized antioxidant enzyme, is able to convert the hydrogen peroxide to 
water and oxygen (Young and Woodside, 2001).  
 
Figure 1.3 The sources and cellular responses to ROS. [Adapted from 
(Finkel and Holbrook, 2000)]. 
 
At present, there is accumulating evidence suggesting that ROS trigger 
apoptosis via either mitochondria-dependent or –independent pathways (Circu 
and Aw, 2010; Kasahara et al., 1997; Pierce et al., 1991; Simon et al., 2000; 
Sinha et al., 2013). MAPK signaling pathways including ERK, JNK, p38 
kinase, ERK3/4, and BMK1 (big mitogen-activated protein kinase 1) pathway 
have been identified as important signaling pathways regulated by oxidative 
stress (McCubrey et al., 2006). Especially, JNKs signaling plays an important 
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role in ROS-mediated apoptosis (Circu and Aw, 2010; Dhanasekaran and 
Reddy, 2008; Shen and Liu, 2006). Activation of JNKs by ROS has been 
shown to be involved in both mitochondrial intrinsic apoptotic pathway and 
death receptor-initiated extrinsic pathway (Dhanasekaran and Reddy, 2008). 
For example, activated JNKs translocate to mitochondrial membrane which 
leads to the release of cytochrome C to cytosol, subsequently activates caspase 
9 cascade (Hill et al., 2004; Jiang and Wang, 2000).  
ART contains an endoperoxide bridge and it is believed that the cleavage 
of this endoperoxide bridge catalyzed by iron leads to the production of free 
radicals (Efferth and Oesch, 2004; Meshnick et al., 1993). Indeed, there is 
extensive evidence showing that ART increases ROS production in various 
cancer cells, a process that is found to be critical for ART-mediated cancer cell 
death (Berdelle et al., 2011; Cheng et al., 2013; Du et al., 2010; Efferth et al., 
2007). For example, Efferth et al showed that ART induces ROS-mediated 
apoptosis in doxorubicin-resistant T leukemic cells and addition of antioxidant 
N-Acetyle-Cysteine (NAC) is able to fully inhibit ROS production and block 
ART-induced apoptosis (Efferth et al., 2007). Moreover, this study also 
suggested that ART induces apoptosis via the mitochondrial pathway (Efferth 
et al., 2007). One possible mechanism of ROS underlying ART-induced cell 
death is that ROS cause oxidative DNA damage and sustain DNA double-
strand breaks (Berdelle et al., 2011). Similar findings have also been found in 
breast cancer cells and lysosomes have been identified to function upstream of 
mitochondria ROS production (Hamacher-Brady et al., 2011). However, little 





1.1.3.2 Inhibition of the NF-κB signaling pathways 
NF-κB was first discovered in 1986 as a transcriptional factor which 
interacts with the enhancer element of the immunoglobulin kappa light-chain 
of activated B cells (Sen and Baltimore, 1986). The NF-κB family consists of 
5 proteins: RelA (p65), RelB, c-Rel, p50 (NF-κB1), and p52 (NF-κB2). These 
subunits form dimers to be functional. For example, RelA/p50, the canonical 
or classical pathway, controls the transcription of targeted genes when 
translocates to nuclear upon activation (Gasparini et al., 2014).  
NF-κB is not only involved in the inflammation as we have summarized 
earlier, but also plays double-edged roles in cancer (Hoesel and Schmid, 2013). 
On one hand, NF-κB is constitutively activated in most malignancies and 
possesses pro-tumorigenic function (Fuchs, 2013; Gasparini et al., 2014; 
Vaiopoulos et al., 2013). On the other hand, activation of NF-κB is able to 
activate the adaptive immune response by regulating the expression of 
important components in the innate immune response system to suppress 
tumorigenesis (Liang et al., 2004).  
ART has been shown to inhibit NF-κB activity (Li et al., 2009; Li et al., 
2013; Thanaketpaisarn et al., 2011). Li et al showed that RelA (p65) 
expression level as well as its transcription activity was reduced by ART in 
mouse myeloma SP2/0 cells, which is believed to be critical for ART-induced 
cell cycle arrest and apoptosis (Li et al., 2009). Subsequently, ART was shown 
to completely inhibit TRAIL-induced NF-κB transcriptional activation and 
down-regulate the expression of pro-survival proteins such as survivin, XIAP 
and Bcl-XL in human cervical cancer cell line HeLa (Thanaketpaisarn et al., 
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2011). The authors also showed that ART significantly enhances TRAIL-
induced apoptosis (Thanaketpaisarn et al., 2011).  
 
1.1.3.3 Inhibition of the PI3K-Akt signaling pathway 
Phosphatidylinositol 3-kinases (PI3Ks) are a family of lipid kinases that 
functions upstream of intricate intracellular signaling networks (Cantley, 
2002). They play a central role in regulating cell cycle, cell survival, protein 
synthesis and cell motility (Cantley, 2002). Based on the in vitro substrate 
specificity, structure and the mode of regulation, PI3Ks have been classified 
into three groups (class I-III) (Vanhaesebroeck et al., 1997). Among the three 
classes, class I PI3Ks can be divided into two subclasses, IA and IB 
(Vanhaesebroeck et al., 1997).  
The serine/threonine kinase Akt, as called protein kinase B (PKB), is one 
of the most important downstream targets of PI3Ks (Vanhaesebroeck et al., 
1997). Upon stimulation with growth factors such as insulin, 
phosphatidylinositol-3,4,5-trisphosphate [PI-(3,4,5)-P3] will be generated 
which is catalyzed by PI3Ks (Cantley, 2002). Interaction of Akt with PI-
(3,4,5)-P3 leads to the translocation of Akt to plasma membrane, whereby it is 
phosphorylated by phosphoinositide-dependent kinase 1 (PDK1) and 
phosphoinositide-dependent kinase 2 (PDK2) (Fresno Vara et al., 2004). 
PDK2 was later found as the mammalian target of rapamycin complex 2 
(mTORC2) and the dual phosphorylation is required for Akt activation and its 
function such as regulation of cell growth, cell proliferation and cell survival 
(Garcia-Echeverria and Sellers, 2008; Jacinto et al., 2006). In addition, 
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activated Akt has also been found to promote angiogenesis in tumor (Fang et 
al., 2007; Hamada et al., 2005). 
The effect of ART on the PI3K-Akt pathway in cancer cells is less studied. 
In human cervical cancer HeLa cells, it has been shown that ART suppresses 
the Akt phosphorylation induced by TRAIL (Thanaketpaisarn et al., 2011). 
However, their results also showed that ART treatment alone fails to decrease 
the phosphorylation of Akt. At present, it remains unclear how ART inhibits 
TRAIL-induced Akt phosphorylation. 
 
1.2. AUTOPHAGY 
1.2.1 Overview of autophagy 
Autophagy refers to a catabolic process in which the intracellular 
components are delivered to the lysosomes (mammalians) or vacuoles (plant 
and yeast) for their turnover (Boya et al., 2013). There are three major types of 
autophagy in mammalian cells: chaperone-mediated autophagy (CMA), 
microautophagy and macroautophagy. CMA is a process that has been 
identified only in mammalian cells. In CMA, Hsc70/co-chaperones first 
recognizes the substrate protein and then binds with lysosome-associated 
membrane protein type 2A (LAMP-2A) to unfold the substrate. The unfolded 
protein is then translocated to lysosomes for degradation (Kaushik and Cuervo, 
2012). Microautophagy transfers cytosolic components into the lysosome or 
vacuole for degradation via invaginations of the lysosomal or vacuolar 
membrane and subsequently pinch off into the lysosomal lumen for 
degradation (Mijaljica et al., 2011). Macroautophagy is an evolutionarily well 
conserved catabolic process in which cellular proteins and organelles are first 
20 
 
engulfed to double-membrane vesicle, termed as autophagosome, and then 
delivered to lysosomes for degradation (Yang and Klionsky, 2010).  
Among three types of autophagy, macroautophagy (referred as 
autophagy hereafter) is the most well studied and characterized process. 
Autophagy functions as a recycling system to maintain the cellular renovation 
and homeostasis (Mizushima and Komatsu, 2011). As a dynamic process, 
autophagy involves four consecutive steps: initiation, nucleation, elongation, 
and maturation (Figure 1.4). The successful identification of AuTophaGy-
related (ATG) genes in yeast facilitates the autophagy study in mammalians. 
So far, more than 30 Atg genes have been identified in yeast and many of 
those have mammalian homologues (Mehrpour et al., 2010). The ATG 
proteins are the machinery in executing autophagic processes (Mehrpour et al., 
2010). 
 
Figure 1.4 Different stages of autophagy in mammals. [Modified from 
(Zhou et al., 2013a)]. 
 
1.2.2 Stages of autophagy  
1.2.2.1 Initiation 
The initiation process depends on the activation of the Atg1 complex 
in yeast or ULK (Unc-51-like kinases) complex in mammalians. In yeast, the 
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complex consists of Atg1, Atg13 and the Atg17–Atg31–Atg29 subcomplex. 
The mammalian ULK (homolog of Atg1) complex contains ULK1 or ULK2, 
ATG13, FIP200 (family-interacting protein of 200 kD) and ATG101 (an 
ATG13-binding protein) (Chen and Klionsky, 2011). ULK1 has been 
demonstrated to be essential for autophagic signaling pathway instead of 
ULK2 (Chan et al., 2007; Lee and Tournier, 2011)  
The activity of ULK complex is regulated by mammalian target of 
rapamycin complex 1 (mTORC1), which is now also named as mechanistic 
target of rapamycin complex 1. Studies have shown that ATG13 and ULKs 
(ULK1 and ULK2) are the substrates of mTORC1 that can be directly 
phosphorylated by mTORC1, which leads to the inactivation of ULK and 
subsequent suppression of autophagy (Hosokawa et al., 2009; Jung et al., 
2009). Later on, Kim et al. identified the phosphorylation site of ULK1 by 
mTORC1. The study showed that mTORC1 direct phosphorylates ULK1 at 
Ser757 to suppress its activity under nutrient sufficient condition (Kim et al., 
2011). Furthermore, there is evidence linking AMPK directly to the autophagy 
machinery, based on observations that under energy stress conditions, 
activated AMPK is able to directly phosphorylate ULK1 to promote 
autophagy (Egan et al., 2011; Kim et al., 2011). 
 
1.2.2.2 Nucleation 
Nucleation refers to the recruitment of Atg proteins such as Atg1 
(ULK) complex, Atg9 and Atg18 to the yeast phagophore assembly site (PAS) 
or to PAS equivalent in mammalians (Chen and Klionsky, 2011). PAS is a 
proposed site for the autophagosome formation and the exact structure may 
22 
 
vary in different stages of autophagsosome formation (Xie and Klionsky, 
2007). The activation of PI3K complex is essential for the nucleation and 
assembly of the phagophore membrane (Mehrpour et al., 2010). In 
mammalian cells, the core components of this complex are class III PI3K or 
hVps34 (hereafter refers as hVps34), protein kinase p150 or hVps15 and 
Beclin 1 (the homolog of yeast Atg6) (Chen and Klionsky, 2011; Funderburk 
et al., 2010). 
The emerging binding partners of hVps34 complex are unveiling its 
functions in autophagy (Funderburk et al., 2010). The binding partners can be 
divided into two groups based on their regulatory roles in the autophagic 
process. ATG14L (Atg14-like protein, the homolog of yeast Atg14, also 
known as Barkor) and UV radiation resistance-associated gene (UVRAG) 
protein are capable of promoting autophagy via direct binding with Beclin-1 
(Liang et al., 2006; Matsunaga et al., 2009). In addition, activating molecule in 
beclin-1-regulated autophagy (AMBRA1) and Bax-interacting factor 1 (Bif1) 
are also shown to positively regulate autophagy (Di Bartolomeo et al., 2010; 
Fimia et al., 2007; Takahashi et al., 2007). On the other hand, Run domain 
protein as Beclin-1 interacting and cystein-rich containing (Rubicon) and anti-
apoptotic cellular Bcl-2 (cBcl-2) negatively regulate autophagy through 
interaction with UVRAG or Beclin-1, respectively (Liang et al., 2006; 
Matsunaga et al., 2009). Among these regulators, the binding of AMBRA1, 






Elongation is the process for the vesicle expansion and completion of 
autophagosome formation mediated by concerted actions of the autophagy 
machinery (Chen and Klionsky, 2011; Suzuki et al., 2001). Two ubiquitin-like 
conjugation systems, Atg12-Atg5 system and LC3/Atg8 system are required 
for the completion of autophagosomes.  
For the conjugation reaction of Atg12 to Atg5, it is catalyzed by E1-
like enzyme Atg7 and E2-like enzyme Atg10, which have been shown as a 
conserved system (Mizushima et al., 1998). For the conjugation of Atg8 to 
phosphatidylethanolamine (PE), it is catalyzed by Atg7 and E2-like enzyme 
Atg3 (Geng and Klionsky, 2008; Yamada et al., 2007). Atg12-Atg5 conjugate 
together with Atg16 has been reported to have an E3-like activity for Atg8 
lipidation by stimulating the activity of Atg3 (Fujita et al., 2008; Hanada et al., 
2007). In addition, Atg12–Atg5-Atg16 complex is also shown to be required 
for the correct localization of Atg8/LC3 (Fujita et al., 2008; Mizushima et al., 
2001) 
LC3 (microtubule-associated protein light chain 3), the homolog of 
Atg8, was first identified by Yoshimori’s group in 2000 (Kabeya et al., 2000). 
There are two forms of LC3, cytosolic form LC3-I and membrane bound form 
LC3-II. During the autophagosome formation, the arginine residue from LC3 
precursor is removed by ATG4B, which results in the formation of LC3-I. 
LC3-I is then conjugated with PE catalyzed by ATG7 and ATG3 to become a 
membrane-bound form, LC3-II. The conjugated form of LC3 is reversible and 
the PE can be removed by ATG4B after the vesicle completion (Geng and 
Klionsky, 2008; Kabeya et al., 2004). LC3-II specifically associates with 
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autophagosomes and its amount correlates with the extent of autophagosome 
formation (Kabeya et al., 2000). Therefore, it has been widely used as an 
autophosome marker to indicate the autophagic process. 
In addition to LC3, there are some other forms of Atg8 homologs in 
mammalian cells including γ-aminobutyric acid type A receptor associated 
protein (GABARAP) and GABARAP-like 1, 2 and 3, all of which are 
indispensable for the autophagic process although they act differently in 
autophagosome formation (Kabeya et al., 2004; Weidberg et al., 2010). LC3 
mediates the expansion of phagophore membrane, whereas the GABARAP 
family is required for the maturation of autophagosome (Weidberg et al., 
2010). 
 
1.2.2.4 Maturation and degradation 
Once autophagosome formation is completed, it then fuses with 
lysosome to form autolysosome, in which degradation of cytosolic cargos 
occurs (Chen and Klionsky, 2011). The late stage of autophagy is controlled 
tightly by different players (Rubinsztein et al., 2012). First, UVRAG interacts 
with hVps34 complex to upregulate the maturation of autophagosomes via 
stimulation of RAB7 GTPase activity while Rubicon interacts with UVRAG 
with the opposite function (Liang et al., 2008; Matsunaga et al., 2009). Second, 
small GTPase RAB7 and SNARE proteins such as VAMP8 and VTI1B 
control the endosomes and lysosomes fusion with autophagosomes (Furuta et 
al., 2010; Gutierrez et al., 2004). Third, V-ATPase that localizes at lysosomal 
membrane is required for the lysosomal acidification which its inhibition will 
block the transfer of endocytosed material from late endosomes to lysosomes 
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(Mousavi et al., 2001). In other words, V-ATPase inhibitors inhibit the 
maturation and degradation of auophagosomes. Fourth, Atg22 is required for 
the efflux of amino acid produced from autophagic degradation (Yang et al., 
2006). And finally Spinster, a late endosomal and lysosomal memebrane 
protein with sugar transporter activity, is essential for the reformation of 
lysosome (Rong et al., 2011). 
 
1.2.3 Biological functions of autophagy  
1.2.3.1 Overview of biological functions of autophagy 
Under nutrient-rich conditions, there is a low basal level of autophagy 
which is required for cellular homeostasis through constitutive turnover of 
cytopolasmic components (Kuma and Mizushima, 2010; Mizushima, 2005). 
Under nutrient starvation or other stressed conditions, autophagy is induced as 
an adaptive response. Therefore, the primary role of autophagy is to maintain 
intracellular homeostasis via degradation of cellular components to produce 
amino acid in nutrient starvation condition and then regress the retired tissues 
(Mizushima, 2005). In addition to the starvation adaptation, autophagy has 
been well-studied to be involved in a greater variety of physiological 
processes, including turnover of unfolded proteins or/and damaged organelles, 
cell metabolism, development, aging, immunity and cell death (Boya et al., 
2013; Deretic and Levine, 2009). Here we mainly focus on its role in cell 




1.2.3.2 Autophagy in cell survival 
Autophagy has evolved as a conserved mechanism for cell survival under 
stressed condition (Nishida et al., 2009). It has been demonstrated in various 
studies that defects in autophagy have been associated with an increased 
susceptibility to death in models ranging from yeast to mammals (Kuma et al., 
2004; Tsukada and Ohsumi, 1993; Yue et al., 2003). Generally speaking, 
amino acid production via autophagic pathway is required for protein 
synthesis, gluconeogenesis and energy production (Mizushima, 2007).  
In yeast, it has been demonstrated that there is a reduction of amino acid 
level as well as suppression of newly synthesized protein in autophagy-
deficient cells under nitrogen starvation (Onodera and Ohsumi, 2005). The cell 
viability of these mutants was found to be lost faster than the wide type cells 
under nitrogen starvation (Tsukada and Ohsumi, 1993). Similar findings were 
also found in mammals. During neonatal starvation period, the neonatal 
lethality has been observed in mice with Atg3, Atg5 and Atg7 deletion with 
reduction of amino acid level in tissues and plasma (Komatsu et al., 2005; Kuma 
et al., 2004; Sou et al., 2008).  
Moreover, amino acids can participate in the tricarboxylic acid (TCA) cycle 
to mediate the ATP production (Mizushima, 2007). Such a notion is supported by 
several studies, which autophagy defects lead to a reduction in ATP production 
and thus reduced cell viability under starvation condition (Guo et al., 2011; Lum 
et al., 2005; Qu et al., 2007). Moreover, it is further confirmed by the findings that 
addition of TCA metabolic substrates such as methylpyruvate reverses the cell 
death effect of autophagy defects (Lum et al., 2005; Qu et al., 2007).  
In addition, amino acid has also been shown to be converted to glucose 
via hepatic gluconeogenesis in liver (Ezaki et al., 2011). In their study, 
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absence of amino acids released from autophagic proteolysis in liver specific 
Atg7-deficient mice led to reduced level of glucose. Thus, Ezaki et al. 
provided a novel mechanism for the pro-survival function of autophagy under 
starvation condition.  
The pro-survival function of autophagy is not only found in nutrient 
deprivation, but also in other stress conditions such as endoplasmic reticulum 
stress or genotoxic stress (Ding et al., 2007; Ogata et al., 2006; Qiang et al., 
2013). It has been demonstrated that autophagy promotes cell survival via 
suppression of p62-mediated p38 activation in response to carcinogen-induced 
genotoxic stress (Qiang et al., 2013). Moreover, autophagy increases cell 
viability during extracellular matrix detachment in epithelial cells (Fung et al., 
2008). 
 
1.2.3.3 Autophagy in cell death 
Basically, autophagic cell death needs to meet the following 3 criteria: (i) 
cell death occurs without the involvement of apoptosis; (ii) there is an increase 
of autophagic flux, and not just an increase of the autophagic markers, in the 
dying cells; and (iii) suppression of autophagy via both pharmacological 
inhibitors and genetic approaches is able to rescue or prevent cell death (Shen 
and Codogno, 2011). A typical example of autophagic cell death in mammals 
is apoptotic stimuli etoposide, staurosporine and thapsigargin induce non-
apoptotic death in Bax/Bak double knockout mice embryonic fibroblasts 
(Bax/Bak–/– MEFs) with induction of autophagy (Shimizu et al., 2004). 
Moreover, the cell death can be inhibited by autophagy inhibitor 3-methyl 
adenine (3-MA) and it requires the involvement of autophagic proteins ATG5 
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and Beclin 1 (Shimizu et al., 2004). However, the term “autophagic cell death” 
has been questioned as it is only shown in the complete deficiency of the 
apoptosis machinery which is not that common in higher eukaryotes under 
physiological and pathological conditions (Shen and Codogno, 2011; Shen et 
al., 2012). 
Nevertheless, crosstalks do exist between autophagy and apoptosis (Liang 
et al., 2007; Maiuri et al., 2007; Yousefi et al., 2006). Therefore, it is possible 
that autophagy promotes cell death via enhancing apoptosis or even necrosis. 
Actually, there is accumulating evidence suggesting the pro-death role of 
autophagy (Bonapace et al., 2010; Espert et al., 2006; Scott et al., 2007). In 
Drasophila, high level of autophagy caused by the overexpression of Atg1 
induces apoptotic cell death (Scott et al., 2007). It has also been shown that 
HIV-1 envelope glycoproteins-induced autophagy is required for triggering 
CD4+ T cell apoptosis as blockade of autophagy by either drugs (3-
methyladenine and bafilomycin A1) or siRNAs knockdown for Beclin 1/Atg6 
and Atg7 genes inhibits apoptosis (Espert et al., 2006). In addition, autophagy 
has also been demonstrated to promote necroptosis as evidenced by the 
combination of rapamycin with the glucocorticoid dexamethasone (Bonapace 
et al., 2010). 
With regards to the mechanisms of the pro-death function of autophagy, 
Nezis et al. showed that autophagy acts genetically as the upstream of caspase 
activation and DNA fragmentation in Drosophila late oogenesis, indicating 
that autophagy directly contributes to the activation of cell death (Nezis et al., 
2010). Moreover, autophagy disrupts the intracellular ROS balance via 
degradation of catalase, a key enzymatic ROS scavenger, which results in 
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accumulation of ROS in the cells. Subsequently, this ROS imbalance leads to 
membrane peroxidation, loss of membrane integrity and eventually cell death 
(Yu et al., 2006). 
 
1.2.4 Implications of autophagy in human diseases 
1.2.4.1 Overview  
Owning to its significant roles in various biological functions, autophagy 
has been well-established to be implicated in the development of various 
human diseases including neurodegenerative diseases, metabolic disorders, 
infectious diseases and cancer (Rubinsztein et al., 2012). Because most of 
neurodegenerative disease-associated proteins such as full-length mutant 
huntingtin are autophagy substrates, impairment of clearance by inhibition of 
autophagy slows down the degradation of those proteins which may cause 
Huntington’s disease (Ravikumar et al., 2002). In their study, the authors 
showed that induction of autophagy by mTORC1 inhibition enhances the 
clearance of aggregate-prone proteins, suggesting that autophagy induction 
can be utilized as a therapeutic strategy for certain neurodegenerative diseases 
(Ravikumar et al., 2002). This is probably the first study showing that 
autophagy clears intracytoplasmic aggregation-prone proteins. Importantly, 
subsequent studies further support this notion, based on the evidence that 
activation of the autophagic process facilitates the clearance of the protein 
aggregates in Parkinson's disease, Alzheimer's disease and Huntington's 
disease (Berger et al., 2006; Webb et al., 2003; Yu et al., 2005). In two in vivo 
mouse models with neuronal-specific knockouts of Atg5 or Atg7, 
neurodegeneration have been observed which are considered to be caused by 
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the excessive accumulation of abnormal neuroproteins (Hara et al., 2006; 
Komatsu et al., 2006). In the meantime, the failure in the clearance of lipid 
droplets in hepatocyte-specific knockout of Atg7 leads to elevated levels of 
hepatic lipids in mice, which may be relevant to metabolic disease such as 
obesity (Singh et al., 2009).  
 
1.2.4.2 Involvement of autophagy in cancer 
The complex role of autophagy is not only shown in cell survival and cell 
death but also in cancer. On one hand, autophagy prevents tumorigenesis 
which may function as a tumor suppressor. On the other hand, in established 
cancers, it helps the cancer cell growth under metabolic stress and promotes 
tumor survival in response to chemotherapeutic agents (Rubinsztein et al., 
2012). Therefore, it has been widely recognized that autophagy is double-
edged sword in cancer (White and DiPaola, 2009). 
The link between autophagy and cancer was first observed by Liang et al. 
in which spontaneous tumors were found in mice with deletion of Beclin-1 
(Liang et al., 1999). Subsequently, several other Atgs such as Atg7 and Atg4C 
were also found to be involved in anti-tumorigenesis (Komatsu et al., 2005; 
Marino et al., 2007). In addition, deletion of Bif-1, the positive mediator of the 
Beclin-1/Vps34 complex, enhances the tumor development (Takahashi et al., 
2007). This tumor suppressive function of autophagy may due to the clearance 
of oncogenic protein substrates, toxic unfolded proteins and damaged 
organelles, which subsequently leads to the suppression of chronic tissue 
damage as well as inflammation and maintenance of the genome stability 
(Guo et al., 2013b; Karantza-Wadsworth et al., 2007; White, 2012).  
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On the other hand, some recent studies suggest the pro-cancer function of 
autophagy via depletion of autophagy essential genes. For example, studies 
from White’s group showed that autophagy inhibition by depletion of Atg5 or 
Atg7 reduces Ras-mediated tumor growth (Guo et al., 2011). They further 
demonstrated that the preserve of mitochondrial function and lipid metabolism 
or glutamine metabolism by autophagy is required for the tumorigenesis in K-
ras-driven and BrafV600E-driven lung tumor (Guo et al., 2013a; Strohecker et 
al., 2013; Strohecker and White, 2014). Studies from another group also 
showed that suppression of autophagy via ablation of FIP200 significantly 
reduces the growth of established tumors in vivo (Wei et al., 2011). A very 
recent report from this group demonstrated that FIP200 is indeed required for 
maintaining tumor growth via activation of the NF-kB pathway mediated by 
p62 (Wei et al., 2014).  
In addition, a number of studies have demonstrated that some cancer cells 
have a much higher basal level of autophagic activity that is mainly induced 
by metabolic stress. This higher basal autophagic level protects cancer cells 
from apoptosis and necrosis in both in vitro and in vivo models. (Abedin et al., 
2007; Li et al., 2010). Moreover, in response to most anti-cancer reagents, 
autophagy was also shown to be induced in cancer cells as a cell survival 
mechanism and thus reduced the efficiency of drugs (Degenhardt et al., 2006; 
Kimmelman, 2011; Samaddar et al., 2008). Therefore, inhibition of autophagy 
is considered as a logical approach in cancer therapy, especially in combined 
treatments with other established anti-cancer drugs (Gupta et al., 2010; 
Kanzawa et al., 2004; Yang et al., 2011). Currently, the autophagy inhibitor 
chloroquine (CQ) as well as its derivatives has been tested in a number of 
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clinical trials, either alone or in combination therapy with other anti-cancer 
agents. (http://clinicaltrials.gov/ct2/results?term=autophagy). Table 1.3 
summarizes the very recent published reports on hydroxychloroquine (HCQ) 
in clinical trials in human cancer patients. Among them, (i) partial responses 
and stable disease were observed in four trials (ii) HCQ 600 mg/d is 
recommended for phase II dose in two trials while HCQ 600 mg twice daily is 
recommended in 3 trials. However, there are still some issues need to be 
addressed for the optimal practice of autophagy inhibition in cancer therapy 
(Guo et al., 2013b). For example, blockage of autophagy in established tumors 
may cause oncocytomas since it has been shown that Atg7 loss converted 
















Patients received HCQ 
(200 to 800 mg oral 
daily) with radiation 
therapy (RT) and 
concurrent and adjuvant 
temozolomide (TMZ). 
HCQ 600 mg/d was found 
to be the maximum 
tolerated dose (MTD) in the 
combination. However, 
autophagy inhibition was 
not consistently achieved in 
patients and no significant 








Phase I Oral HCQ 200 to 1200 
mg daily with dose-
intense oral TMZ 150 
mg/m2 daily for 7/14 
days. 
HCQ 600 mg twice daily 
combined with dose-intense 
TMZ is recommended for 
phase II dose. Prolonged 
stable disease and 






(Vogl et al., 
2014) 
Phase I Combined standard 
doses of bortezomib and 
HCQ (100 mg-1200 mg 
daily). 
HCQ 600 mg twice daily 
with 1.3 mg/m2 bortezomib 
is recommended for phase 
II dose. 45% subjects had a 
period of stable disease and 
14% subjects had very 







Phase I HCQ 600 mg twice 
daily in combination 
with temsirolimus 
(TEM) 25 mg weekly. 
HCQ 600 mg twice daily is 
recommended for phase II 
dose in combination with 
TEM 25 mg weekly. Partial 
responses and stable 
disease were observed in 






et al., 2014) 
Phase I 400-1000 mg daily HCQ 
(day 2 to 21 of a 21 days 
cycle) in combination 
with histone deacetylase 
(HDAC) inhibitor 
vorinostat (VOR) (200-
400 mg daily). 
HCQ 600 mg with 400 mg 
VOR is the maximum 
tolerated dose and 
recommended for phase II 
regimen. A durable partial 
response and prolonged 
stable disease were found 
in 1/24 and 2/24 patients.  
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1.3. REGULATION OF AUTOPHAGY BY MTORC1 AND LYSOSOMES 
1.3.1 Regulation of autophagy by mTOR1 
1.3.1.1 Overview of mTOR 
The serine/threonine protein kinase mTOR exists in two independent 
complexes: mTORC1 and mTORC2. The two complexes have shared units 
including mTOR, mammalian lethal with SEC13 protein 8 (mLST8; also 
known as GβL) and DEP domain-containing mTOR-interacting protein 
(DEPTOR). Two unique proteins are used to distinguish the two complexes: 
regulatory-associated protein of mTOR (RAPTOR) for mTORC1 and 
rapamycin-insensitive companion of mTOR (RICTOR) for mTOC2. It is well-
known that mTOR regulates cell proliferation, metabolism, survival and 
motility via phosphorylation of various substrates such as S6 kinase (S6K) and 
eIF4E binding protein 1 (4E-BP1), and Akt/PKB (Inoki and Guan, 2006; 
Zoncu et al., 2011b). Recently, an interesting study suggests a novel role of 
mTORC1 in proteasome-mediated protein degradation (Zhang et al., 2014b). 
As a central controller of organism growth and homeostasis, emerging 
evidence suggests that it also plays a critical role in human diseases, including 
diabetes, cancer and aging (Cornu et al., 2013; Zoncu et al., 2011b).  
 It has been extensively studied that mTORC1 inhibition induced by 
nutrient starvation such as amino acid starvation or mTOR inhibitors such as 
rapamycin induces autophagy via direct phosphorylation of ULK1 and ATG13 
(Jung et al., 2009; Mehrpour et al., 2010). Therefore, mTORC1 serves as an 
important negative regulator of autophagy. The role of mTORC2 in autophagy 
regulation is less studied. However, it has been demonstrated that 
phosphorylated Akt/PKB mediated by mTORC2 suppresses the activity of the 
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transcription factor Forkhead Box O3 (FoxO3) and FoxO3 has been shown to 
stimulate autophagy in muscle cells by increasing the transcription of several 
Atgs (Mammucari et al., 2007).  
  
1.3.1.2 Regulation of mTORC1  
The activity of mTORC1 is controlled mainly by 3 pathways (Figure 1.5), 
including (i) the amino acid-Rag GTPase pathway where amino acids are 
required for the activation of mTORC1 activity (Sancak et al., 2010; Zoncu et 
al., 2011a), (ii) the class I PI3K-Akt-TSC pathway where mTORC1 is 
activated mainly by growth factors (Inoki et al., 2002; Manning et al., 2002; 
Potter et al., 2002), and (iii) the AMPK pathway. AMPK is activated by 
cellular stress factors such as oxidative stress and disruption of energy 
homeostasis (increased AMP/ATP ratio). Activation of AMPK inhibits 
mTORC1 activity via phosphorylation of TSC2 or raptor (Gwinn et al., 2008; 
Inoki et al., 2006; Inoki et al., 2003b). In addition, mTORC1 can be activated 
by Wnt via inhibition of GSK3 (Inoki et al., 2006). 
Continuous studies from Sabatini laboratory unveil the different 
regulators involved in the amino acid-mediated mTORC1 activation (Bar-
Peled et al., 2013; Bar-Peled et al., 2012; Sancak et al., 2010; Sancak et al., 
2008; Zoncu et al., 2011a). They first identified four Ras-related small 
guanosine triphosphatases (GTPases) proteins, including Rag A, RagB, RagC, 
and RagD which are required for the activation of the mTORC1 by amino 
acids via promoting the translocalization of mTOR to a membrane-bound 
compartment (Sancak et al., 2008). Later on, they identified a complex termed 
as Ragulator, interacts with the Rag GTPases and recruits them to lysosomes 
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for mTORC1 activation (Sancak et al., 2010). V-ATPase and two additional 
Ragulator components (HBXIP and C7orf59) are also found to be necessary 
for amino acids mediated mTORC1 activation (Bar-Peled et al., 2012; Zoncu 
et al., 2011a). They further identified a GATOR complex consisting of 
DEPDC5, Nprl2, and Nprl3 negative regulates Rag GTPases which inhibits 
mTORC1 activity (Bar-Peled et al., 2013). 
PI3K-Akt activates mTORC1 activity mainly via inhibition of tuberous 
sclerosis complex-1 (TSC1) and TSC2 activity (Zoncu et al., 2011b). TSC1 
and TSC2 form a complex that acts as a GTPase activating protein (GAP) for 
the small GTPase Rheb (Garami et al., 2003; Inoki et al., 2003a; Zhang et al., 
2003b). The phosphorylation of TSC2 mediated by Akt inhibits its GAP 
activity for Rheb and thus activates mTORC1. 
 
 




1.3.2 Regulation of autophagy by lysosomes 
Lysosomes, first discovered by Christian de Duve in the 1950s, are 
intracellular organelles that play very important roles in physiological 
processes such as cholesterol homeostasis, plasma membrane repair, pathogen 
defence, cell signaling and cell death (Saftig and Klumperman, 2009). 
Lysosomal hydrolases and integral lysosomal membrane proteins are essential 
for lysosomal function (Saftig and Klumperman, 2009). 
The internal pH of lysosomes is acidic (below 5), which is required for 
maintaining the activity of acid hydrolase. Vacuolar (H+)-ATPase (V-ATPase) 
complex is one of the key factors controlling lysosomal pH. It contains two 
domains: peripheral V1 domain and integral V0 domain. The V1 domain 
needed for ATP hydrolysis consists of eight different subunits (A-H). The V0 
domain is composed of 6 subunits that drives proton from cytoplasm to the 
lumen (Cipriano et al., 2008; Nishi and Forgac, 2002). V-ATPase is active 
when the two domains assemble into a single complex on the lysosomes 
membrane (Trombetta et al., 2003). 
Lysosomes are involved in the maturation/degradation stage during the 
course of autophagy. As autophagosomes fused with lysosomes to form 
autolysosomes, the contents of the autophagosomes will be degraded by 
various hydrolases from the lysosomes (Eskelinen and Saftig, 2009). 
Suppression of lysosomal function will therefore effectively block the 
degradation step of the autophagic process. Both bafilomycin A1 (BAF) and 
chloroquine (CQ) are two of the most commonly used lysosomal inhibitors. 
BAF is known to block maturation of autophagosomes via inhibition of the 
lysosomal V-ATPase activity (Yoshimori et al., 1991); while CQ blocks 
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autophagic degradation by neutralizing the lysosomal pH (Poole and Ohkuma, 
1981). At present, there is a great progress in understanding the role of 
lysosomes in autophagy which has been well documented recently (Shen and 
Mizushima, 2014). Below we will discuss the regulatory mechanism of 
lysosome function.  
 
1.3.3 Regulation of lysosomal function 
1.3.3.1 Regulation of lysosomal function by mTORC1 
In Drosophila fat body, during starvation-induced autophagy there is 
increased LysoTracker staining, suggesting an increase of lysosomal 
acidification and function (Klionsky et al., 2008; Scott et al., 2004). This 
increased lysosomal acidification during starvation has also been observed in 
mammals (Ni et al., 2011). Earlier studies from our laboratory showed that 
lysosomal function is controlled by mTORC1 and the fusion of 
autophagsomes with lysosomes (Zhou et al., 2013b). It was found that 
lysosomal activation during the course of autophagy requires mTORC1 
inhibition and autophagsome-lysosome fusion. In addition, TFEB activation 
has been found to be necessary but not sufficient for lysosomal activation 
under mTORC1 suppression (Zhou et al., 2013b). Another group identified a 
new ion channel, the endolysosomal ATP-sensitive Na+ channel (lysoNaATP), 
which the activity is controlled by mTORC1 (Cang et al., 2013). They found 
that lysoNaATP is consistently open when mTORC1 dissociates from the 
channel during amino acid starvation, thus presenting a novel mechanism via 
which mTORC1 controls lysosomal pH (Cang et al., 2013). However, whether 
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lysosomal function is up-regulated under starvation condition is not 
investigated.  
 
1.3.3.2 Regulation of lysosomal function by TFEB and TFE3 
Earlier studies have shown that the transcription factor EB (TFEB), a 
member of the basic helix-loop-helix leucine-zipper family of TFs, is involved 
in the biogenesis of lysosomes (Sardiello et al., 2009). Subsequently, 471 
TFEB direct targets were identified including the genes related to lysosomal 
enzymes, lysosomal membrane associated proteins and lysosomal V-ATPase 
pumps (Palmieri et al., 2011).  
TFEB is colocalized with mTORC1 on the lysosomal membrane which 
facilitates the phosphorylation mediated by mTORC1 at both Ser142 and 
Ser211 (Martina et al., 2012; Settembre et al., 2012). In addition, it has been 
shown that phosphorylated TFEB binds with 14-3-3 proteins, leading to the 
retention of TFEB in the cytoplasm (Martina et al., 2012; Roczniak-Ferguson 
et al., 2012). Therefore, suppression of mTORC1 activity either by 
pharmacological or genetic inhibition results in the dissociation of TFEB from 
14-3-3 proteins and thus promotes its translocation into the nucleus to initiate 
the transcription of multiple genes related to autophagy and lysosome. In 
addition to mTORC1, ERK2 and protein kinase C (PKC)β have also been 
shown to regulate the TFEB activity (Ferron et al., 2013; Settembre et al., 
2011). However, there is one report showing the opposite effect of mTORC1 
on TFEB: mTORC1 phosphorylates TFEB and promotes its nuclear 
localization (Pena-Llopis et al., 2011). One possibility for such a discrepancy 
is due to the TSC2-deficient cells used (Pena-Llopis et al., 2011). Intriguingly, 
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Settembre et al. observed that mTORC1 inhibition by amino acid starvation, 
Torin 1 or CQ treatment still triggers TFEB nuclear localization in TSC-null 
cells (Settembre et al., 2012). Recently, another transcriptional factor, TFE3, 
was identified to play an important role in promoting the expression of 
lysosomal genes independently of TFEB (Martina et al., 2014). Similar with 
TFEB, the activity of TFE3 is also controlled by mTORC1 and the 
phosphorylated form of TFE3 localizes in cytosol via its binding with 14-3-3 
proteins.  
 
1.3.3.3 Regulation of lysosomal function by V-ATPase 
V-ATPase is the most important factor that regulates lysosomal 
function via regulating its pH. It is a proton-pumping membrane protein 
complex and drives protons against their electrochemical gradient into the 
lysosome lumen by hydrolysis of ATP (Mindell, 2012). The V-ATPase 
complex contains two domains: the peripheral V1 domain and the integral V0 
domain. The V1 domain needed for ATP hydrolysis consists of eight different 
subunits (A-H). The V0 domain composed of 6 subunits drives proton from 
cytoplasm to the lumen (Cipriano et al., 2008; Nishi and Forgac, 2002). Based 
on the reversible disassociation model, V-ATPase is active when the two 
domains assemble into a single complex on the lysosomes membrane 
(Trombetta et al., 2003). Sautin et al. showed that PI3K mediated glucose-
dependent assembly of the V-ATPase in renal epithelial cells (Sautin et al., 





1.3.3.4 Other factors in regulation of lysosomal function 
Besides mTORC1, V-ATPase and TFEB which we have discussed 
above (Figure 1.6), other factors have also been implicated in regulation of 
lysosomal function. For example, one study showed that the depletion of 
LAMTOR1 (late endosomal/lysosomal adaptor, MAPK and mTOR activator 
1), a novel lysosomal membrane adaptor, leads to altered lysosomes 
positioning and activated lysosomal function (Malek et al., 2012). This 
aberrant lysosomal activation produced reactive oxygen species (ROS) and 
triggered p53 dependent cell death (Malek et al., 2012). Results from their 
study also provide clues that reagents which are able to activate lysosomal 
function in cancer cells have the potential to be developed as anti-cancer 
agents. In addition, the successful identification of SNARE (soluble N-
ethylmaleimide-sensitive factor attachment protein receptor) proteins in 
mediating autophagosome–lysosome fusion may also play important roles in 
regulation of lysosomal functions (Shen and Mizushima, 2014). 
 





1.4.1 Overview the role of iron in human body and cells 
Iron is one of the essential elements for human. It takes part in the 
formation of haem and iron–sulphur clusters which will then function as a 
cofactor in a wide variety of metabolic reactions (Rouault, 2013). Iron 
deficiency leads to many adverse effects and diseases such as anemia (Killip et 
al., 2007). However, iron is also involved in the free radicals formation via the 
Fenton reactions. Thus, iron overload may damage the cells and tissues via the 
oxidation of important cellular proteins and DNA, leading to various common 
diseases such as hemochromatosis, hemolyticanemias and nerodegradative 
diseases (Rouault, 2013; Zhang et al., 2014a). Therefore, the iron metabolism 
needs to be tightly regulated. For the systematic iron level, it is mainly 
controlled by the iron hormone hepcidin and its receptor, as well as ferroportin, 
the cellular iron exporter (Ganz, 2013). In mammalian cells, the cellular iron 
homeostasis is mainly achieved via regulating the expression of the transferrin 
receptor (TfR), especially TfR1 to control the iron uptake and the expression 
of ferritin to control the iron cytosolic sequestration (Rouault, 2006). Ferritin 
has also been shown to be degraded in the lysosomes and released iron can be 
utilized by cells under iron depleted conditions (Asano et al., 2011). Figure 1.7 




Figure 1.7 Regulation of intracellular iron. 
 
1.4.2 Iron uptake regulated by TfR1 
TfR1 is a homodimeric type II transmembrane protein. It consists of 
extracellular domain, transmembrane region and cytoplasmic domain (Cheng 
et al., 2004). As shown in Figure 1.7, TfR1 recognizes two Fe3+ iron-bearing 
transferrin and this complex is then endocytosed into the cells. The iron is 
release from transferrin in the endo-lysosomal lumen due to its conformational 
change. The released ferric iron (Fe3+) is then reduced to ferrous iron (Fe2+) by 
six-transmembrane epithelial antigen of prostate-3 (STEAP3), a member of 
the metalloreductase family (Ohgami et al., 2006). Fe2+ is subsequently 
transported into the cytosol from endosomal compartments by divalent metal 
transporter 1 (DMT1) protein (also known as Nramp2, DCT1, or SLC11A2) in 
most cells (Fleming et al., 1998; Gunshin et al., 1997). In macrophages, the 
iron is transported by natural resistance-associated macrophage protein-1 
(Nramp1), which also belongs to solute carrier (SLC) family same as DMT1 
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(Canonne-Hergaux et al., 1999). Finally, the iron free transferrin still binds 
tightly with TfR1 and the complex is then recycled to cell surface whereas 
transferrin dissociates from TfR1 due to the extracellular neutral pH (Cheng et 
al., 2004; Hentze et al., 2004).  
Although there is some evidence showing that some transferrin can be 
taken up by cells via TfR1-independent endocytosis in hepatocytes such as 
TfR2-mediated endocytosis or by fluid-phase endocytosis (Lawen and Lane, 
2013), TfR1 plays a major role in the regulation of iron uptake.  
 
1.4.3 Iron storage protein ferritin 
1.4.3.1 Overview of ferritin  
Ferritin, the major iron storage protein in mammals, is composed of 24 
subunits which form a hollow shell with 4,3,2 point symmetry (Harrison and 
Arosio, 1996). This characteristic structure enables the ferritin to store up to 
4500 Fe(III) atoms. There are two subunits of ferritin: ferritin heavy chain 
(FTH, Mr ≈ 22,000) and ferritin light chain (FTL, Mr ≈ 20,000). FTL plays a 
role in facilitating iron clearance from the ferroxidase center of the H-subunit 
as well as the iron nucleation and mineralization (Bou-Abdallah, 2010). FTH 
has a ferroxidase activity that can oxidize the Fe2+ to Fe3+. The oxidation of 
iron ions thus prevents the Fenton reactions and reduces the ROS level. 
Overexpression of FTH in HeLa cells has been shown to reduce half of the 
free iron level and subsequently leads to reduction of cell growth and 
increased resistance to oxidative stress (Cozzi et al., 2000). Down-regulation 
the expression of FTH gene increases the intracellular iron pool, which has 
been shown to be required for cell transformation by c-MYC (Wu et al., 1999). 
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Depletion of the FTH gene Fth in mice results in embryos death within 9.5 
days (Ferreira et al., 2000).  
Ferritin is mainly localized in the cytosol and it can also be found in the 
nuclear, lysosomes and mitochondria (Lawen and Lane, 2013). Although the 
mitochondria ferritin (MtF) has similar functions to cytoplasmic ferritin, it is 
encoded by an intronless gene and it specifically targets to mitochondria (Levi 
et al., 2001). Moreover, the expression of MtF appears to correlate more with 
mitochondrial number than with iron level in the cells (Drysdale et al., 2002).  
 
1.4.3.2 Ferritin degradation 
As the most important iron storage protein, ferritin can be degraded to 
release iron (Asano et al., 2011; Mancias et al., 2014). Trytu et al. utilized 
radioactive-labeled method to investigate the ferritin degradation in rat 
hepatoma cells and found enhanced ferritin degradation and iron release in the 
absence of ferric ammonium citrate (FAC) (Truty et al., 2001). In contrast, 
addition of FAC led to a time-dependent increase of ferritin protein synthesis 
(Truty et al., 2001). 
Meanwhile, there is increasing understanding of the molecular 
mechanisms controlling ferritin degradation in the cells. Kork et al. showed 
that suppression of lysosomal or protesomal activity increases the ferritin 
protein level in melanoma cells (Kwok and Richardson, 2004). It was later 
shown that the degradation of ferritin requires lysosomal activity when the 
cells were exposed to an iron chelator deferoxamine mesylate (DFO) in 
several tumor cell lines (Kidane et al., 2006). Domenico et al. further 
confirmed that ferritin degradation is performed by the lysosomal pathway in 
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response to DFO (De Domenico et al., 2009). Their study also showed that 
ferritin can be degraded by the proteasomal pathway when autophagy pathway 
is blocked. Asano et al. further illustrated that it is the acidic lumen of the 
lysosome that is essential for the iron extraction from ferritin (Asano et al., 
2011). They identified the different models of ferritin degradation in primary 
cells and cancer cells: ferritin is degraded regardless of iron level in primary 
cells while ferritin is only degraded under iron-starvation conditions in cancer 
cells. Such a difference may contribute to the resistance of cancer cells to the 
iron toxicity. Recently, one adaptor protein, nuclear receptor coactivator 4 
(NCOA4) has been identified to be required for the delivery of ferritin from 
cytosol to the lysosomes (Mancias et al., 2014). The authors provided strong 
evidence showing that down-regulation of NCOA4 suppresses the ferritin 
degradation while up-regulation of NCOA4 enhances the turnover of ferritin. 
Moreover, reduced cellular iron availability was observed in NCOA4 deficient 
cells, leading to an increase of cell viability to ROS damage (Mancias et al., 
2014). 
 
1.4.4 Iron responsive protein (IRP)/Iron responsive element (IRE) 
system 
Due to the critical role of TfR1 and ferritin in keeping the iron 
homeostasis as mentioned above, the expression of both proteins are tightly 
controlled by the iron responsive proteins (IRPs)/Iron responsive elements 
(IREs) system (Rouault, 2006). IRPs including IRP1 and IRP2 are mammalian 
proteins which register the cytosolic iron availability and post-transcriptionally 
regulate the expression of iron metabolism genes including TfR1 and ferritin. 
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IREs are found in the mRNAs of ferritin, TfR1 and other iron metabolism 
transcripts (Pantopoulos, 2004). There are five IRE copies in the 
3’untranslated region (UTR) of TfR1 mRNA and in contrast, there is only one 
IRE in the 5’UTR of FTH and FTL mRNA. As shown in Figure 1.8, under 
iron depletion conditions, IPRs bind to IREs of TfR1, FTH and FTL, resulting 
in stabilization of TfR1 mRNA and inhibition of ferritin translation. As a 
result, the uptake of transferrin-bounded iron by TfR1 will be increased while 
the sequestration of iron in ferritin decreases. Conversely, under the iron-rich 
conditions, IRPs fail to bind to IRE. Thus, ferritin and other transcripts with 
5’-UTR are translated and TfR1 with 3’-UTR is cleaved by endonuclease and 
then undergoes degradation.  
Although IRP1 and IRP2 are homologues, there are studies showing that 
IRP2 plays a dominant role in regulating iron homeostasis, based on the 
following observations: (i) IRP2 is degraded in an iron-dependent manner in 
iron-replete cells (Guo et al., 1994; Samaniego et al., 1994); and (ii) genetic 
ablation of IRP2 in mice disrupts iron metabolism whereas depletion of IRP1 
has little effect on regulation of iron homeostasis except in brown fat and 
kidney where the IRP1 level is much higher than IRP2 (Galy et al., 2005; 




Figure 1.8 The expression of ferritin and TfR regulated by IPR/IRE 
system. [Adapted from (Rouault, 2006)]. 
 
 
1.5. GAP OF KNOWLEDGE AND OBJECTIVES  
At present, the molecular mechanisms underlying the anti-cancer function 
of ART remain elusive. Moreover, the effect of ART on autophagy is still 
controversial. On one hand, ART has been shown to inhibit autophagy via 
inhibition autophagsome turnover. On the other hand, there is evidence 
showing that ART induces autophagy by up-regulation of Beclin-1 expression. 
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In addition, lysosome has been shown to be involved in ART-induced cell 
death, while the underlying mechanism is largely unknown. Therefore, we 
hypothesize that ART promotes cell death via regulating lysosomal functions. 
Thus, the main objective of this study is to uncover the mechanisms of ART-
induced cell death by focusing on autophagy and lysosomes. We aimed to 
conduct the following two main aspects of study: 
1. To study the effect of ART on autophagy and lysosomes. 
2. To investigate the implication of lysosomes and the underlying 
molecular mechanism in ART-mediated cell death.  
Data from the present study will reveal novel insights into the molecular 











CHAPTER 2.  




2.1. CELL CULTURE  
HeLa and HepG2 cells were obtained from American Type Culture 
Collection. The GFP-LC3-expressing stable HeLa cells were provided by Dr 
N Mizushima (Tokyo Medical and Dental University, Japan), TSC2-WT and 
TSC2-KO MEFs were obtained from Dr. DJ Kwiatkowski (Zhang et al., 
2003a). All cell lines were maintained in Dulbecco's Modified Eagle Medium 
(DMEM, Sigma-Aldrich, St Louis, MO, D1152) containing 10% fetal bovine 
serum (FBS) (HyClone, Utah, SV30160.03) in a 5% CO2 atmosphere at 37°C.  
 
2.2. CHEMICALS, REAGENTS, AND ANTIBODIES 
The chemicals used in our experiments were as follows: 
Artesunate (ART, Sigma-Aldrich, A3731), Deferoxamine mesylate salt 
(DFO, Sigma-Aldrich, D9533), Z-VAD-FMK (ENZO, BML-P416), 
bafilomycin A1 (BAF, Sigma-Aldrich, B1793), chloroquine diphosphate (CQ, 
Sigma-Aldrich, C6628), N-Acetyl-L-cysteine (NAC, Merk Millipore, Billerica, 
MA, 616-91-1), cycloheximide (CHX, Sigma-Aldrich, 01810), Human TNFα 
(hTNFα, R&D system, 210-TA/CF), fluorescent-labelled ART (LynxTag-
ARTTM ASBlue, BioLynx Technologies, Singapore), LysoTracker Red DND-99 
(Life technologies, Grand Island, NY, L7528), LysoTracker Green DND-26 
(LTG, Life technologies, L7526), MitoTrakcer Red CMXRos (MTR, Life 
technologies, M7512), Magic RedTM cathepsin B reagent (Immunochemistry 
Technologies, LLC, 938), Magic RedTM cathepsin L reagent 
(Immunochemistry Technologies, LLC, 942), DQ Red BSA (Life technologies, 
D12051), MitoSOXTM Red (Life technologies, M36008), CM-H2DCFDA 
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(Life technologies, C6827), Duolink In Situ Red Starter Kit Mouse/Goat 
(Sigma-Aldrich).  
Antibodies were obtained as indicated in the following: anti-LC3 antibody 
(Sigma-Aldrich, L7543), anti-ATG7 antibody (ProScience, Woburn, MA, 
3617), anti-p62 antibody (Abnova, Taipei, H00008878-2C11), anti-tubulin 
(Sigma-Aldrich, T6199), anti-Flag (Sigma-Aldrich, F3165), anti-β-actin 
(Sigma-Aldrich, A5441), anti-V-ATPase D1 (Santa Cruz Biotechnology, SC-
69105), anti-V-ATPase B2 (Santa Cruz Biotechnology, Dallas, Texas, SC-
166122), anti-FTH (Abcam, Cambridge, ab65080), anti-FTL (Abcam, 
ab69090), anti-TFEB (Bethyl Laboratories, Montgomery, TX, A303-673A), 
anti-NCOA4 (Sigma-Aldrich, SAB1404569). All the other antibodies were 
purchased from Cell Signaling Technology (CST, Danvers, MA): anti-
lysosome associated membrane protein 1 (LAMP-1) antibody (CST, 3243S 
and 9091S), anti-phospho-S6 (CST, 2211), anti-S6 (CST, 2217), caspase 3 
(CST, 9662), anti-PARP-1 (CST, 9542), Alexa Fluor 488 goat anti-mouse 
secondary antibody (Life technologies, A-11029); Alexa Fluor 555 donkey 
anti-rabbit secondary antibody (Life technologies, A-31572). 
 
2.3. WESTERN BLOTTING 
After the indicated time of designated treatments, cells were collected and 
rinsed with PBS. The whole cell lysates were prepared in the Laemmli buffer 
(62.5 mM Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, 2mM DTT, phosphatase 
inhibitor and proteinase inhibitor cocktail). Protein concentrations were 
determined by DCTM Protein Assay (Bio-Rad, Hercules,CA, 162-0177). An 
equal amount of protein (30 μg ~ 40 μg) was resolved by SDS-PAGE with 12% 
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acrylamide resolving gel (v/v) and then transferred onto PVDF membrane 
(Bio-Rad) by the wet transfer method at 400 mA for 70 min ~ 90 min (based 
on the size). After blocking with Starting Block Blocking Buffers (Thermo 
Scientific, 37538), the membrane was probed with designated first antibodies 
overnight. After that, the membrane was washed with 1 × Tris Buffered Saline 
with Tween 20 (TBST) for 30 min (10 min × 3 times) and incubated with 
specific second antibodies (5000 times dilution) for 1 h. The membrane was 
developed with the enhanced chemiluminescence method (Thermo Scientific, 
Waltham, MA 34076) and visualized using Kodak Image Station 4000R 
(Kodak, Rochester, NY).  
For the preparation of first antibodies, bovine serum albumin (BSA) 
(Sigma-Aldrich, A9418) was dissolved in 10 ml of 1 × TBST dilution for the 
final concentration of 5%. 0.01% NaN3 was then added to prevent the bacterial 
contamination. The first antibodies were diluted in 1: 1000 antibodies except 
the following: anti-tubulin, anti-actin and anti-LAMP1 with a dilution of 1: 
5000; anti-LC3, anti-p-S6; anti-S6 with a dilution of 1: 2000.  
For the preparation of second antibodies, the second antibody was diluted 
5000 times in 5% non-fat milk (Bio-Rad, 170-6404).  
 
2.4. CONFOCAL IMAGING 
Briefly, cells were first cultured on 8-well Lab-TekTM Chambered 
Coverglass (Thermo Scientific, 155411) overnight followed by designated 
treatment. All the confocal images were obtained with 60 × oil objective 
lenses of Olympus Fluoview FV1000. The images were processed with FV10-




2.5. CELL COLLECTION FOR FLOW CYTOMETRY 
The cells using the flow cytometry in the subsequent experiments were 
seeded in 24-well plate for overnight. Then the cells were performed with 
designated treatments followed by the specific staining (except DQ RED 
BSA). After that, the cells were trypsinized and centrifuged at 4200 rcf. 
Fluorescence intensity of 10,000 cells per sample was measured by flow 
cytometry using the BD FACS cytometer (BD Biosciences, San Jose, CA).   
 
2.6. DETECTION OF CELL DEATH 
Cell death was estimated by morphological changes under phase-contrast 
microscopy and quantified by propidium iodide (PI, 5 µg/ml) exclusion assay 
coupled with flow cytometry (BD Biosciences). For the PI exclusion assay, all 
cells were collected after 48 h designated treatments. Then, resuspended the 
cell pellets with 1 × phosphate buffer saline (PBS) containing 5 μg/ml PI. 
Flow cytometry was then performed to quantify the cell death. Western 
blotting was also used to indicate the cell death via PARP-1 and caspase-3 
cleavages.  
 
2.7. DETECTION OF THE INTRACELLULAR LOCALIZATION OF ART 
The cells were treated with blue fluorescent ART (20 μM, LynxTag-
ARTTMASBlue, from BioLynx Technologies) with or without BAF (50 nM) in 
full DMEM medium for 30 min. Subsequently 50 nM LysoTracker Red DND-
99 (LTR) or MTR was added for 30 min. The cells were washed with PBS 
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twice and DMEM full medium was added into the well followed by 
observation under the confocal microscopy. 
 
2.8. LYSOTRACKER RED (LTR), LYSOTRACKER GREEN (LTG) AND 
MITOTRACKER RED (MTR) STAINING 
The cells were seeded into 8-well chamber or 24-well plate, after the 
designated treatments, cells were incubated with 50 nM LTR or LTG reagents 
in full DMEM medium for 30 min for labeling and tracking acidic organelles 
in live cells. For labeling mitochondria, the cells were incubated with 50 nM 
MTR in PBS for 15 min, then washed twice with PBS followed by incubation 
of full DMEM for the imaging or collection for flow cytometry. The cells in 
Chambered Coverglass were observed under a confocal microscopy. The cells 
from the 24-well plate were collected and the fluorescence intensities were 
measured by flow cytometry. We recorded the fluorescence of LTR and MTR 
using FL-2 channel of FACS. 
 
2.9.  MAGIC RED CATHEPSIN B AND L ACTIVITY ASSAY 
Lysosomal function was also estimated by the catehpsin B and L 
enzymatic activity. Cells were incubated with Magic RedTM cathepsin B or 
cathepsin L reagents for 30 min followed by designated treatments. The cells 
in Chambered Coverglass were observed under a confocal microscopy. The 
cells from the 24-well plate were collected and the fluorescence intensities 
were quantified by flow cytometry. We recorded the fluorescence of Magic 




2.10. DETERMINATION OF PROTEIN PROTEOLYSIS USING DQ RED BSA 
STAINING 
Lysosomal protein proteolysis was estimated by the DQ Red BSA 
staining. Cells were first incubated with DQ Red BSA for 1 h and then washed 
with PBS for 2 times followed by designated treatment. The cells in 
Chambered Coverglass were observed under a confocal microscopy. The cells 
from the 24-well plate were collected and the fluorescence intensities of 
10,000 cells per sample were measured by flow cytometry. We recorded the 
fluorescence of DQ Red BSA using FL-3 channel of FACS. 
 
2.11. IMMUNOFLUORESCENCE STAINING 
Cells were first cultured in 8-well Chambered Coverglass overnight. After 
designated treatment, cells were first fixed with 4% paraformaldehyde (PFA) 
in PBS for 15 min at 37°C and then permeabilized with 0.01% saponin in PBS 
for 10 min. After blocking with 1% BSA in PBS for 30 min, cells were 
incubated with V-ATPase B2 primary antibody with a 1:100 dilution overnight 
at 4 °C. On the second day, the cells were then incubated with LAMP1 in a 
1:100 dilution (CST, 9091S) for 3 h at room temperature followed by 
incubation with Alexa Fluor 488 goat anti-mouse secondary antibody and 
Alexa Fluor 555 donkey anti-rabbit secondary antibody under darkness for 1 h. 





2.12. USE OF IN SITU PROXIMITY LIGATION ASSAY (PLA) ASSAY TO CHECK 
THE INTERACTION BETWEEN V1 AND V0 IN SITU 
The usage of two different PLA probes with amplifiable DNA reporter enables 
us to visualize and quantify the protein-protein interactions in situ (Tak and 
Firestein, 2001). The HeLa cells were first seeded in 16-well chamber. Treated 
cells were firstly fixed with 4% PFA for 15 min at 37°C and then 
permeabilized with 0.01% saponin in PBS for 10 min followed by blocking it 
with 1% BSA in PBS for 30 min. Cells were then incubated with anti V-
ATPase V1 domain subunit B2 (V1B2) and anti V-ATPase V0 domain subunit 
D1 (V0D1) in a 1:100 dilution, incubated overnight at 4°C. The chamber was 
then performed the procedure based on the manufacturer’s instructions (Olink 
Bioscience, Uppsala, Sweden). 
 
2.13. SMALL INTERFERING RNA (SIRNA) AND TRANSIENT TRANSFECTION 
The scrambled RNAi oligonucleotides (Dharmacon, ON-TARGETplus 
Non-targeting Pool, D-001810-10-05) and siRNAs targeting ATG7 
(Dharmacon, SMARTpool, ON-TARGETplus human ATG7, L-020112-00-
0005, Target Sequences: CCAACACACUCGAGUCUUU; 
GAUCUAAAUCUCAAACUGA; GCCCACAGAUGGAGUAGCA; 
GCCAGAGGAUUCAACAUGA), TFEB (Dharmacon, SMARTpool, ON-
TARGETplus human TFEB, L-009798-00-0005, Target Sequences: 
CAACAGUGCUCCCAAUAGC; GCAGCCACCUGAAUGUGUA; 
UGAAAGGAGACGAAGGUUC; GCAGAUGCCCAACACGCUA) and 
NCOA4 (Dharmacon, SMARTpool, ON-TARGETplus human NCOA4, L-




GAGAAGUGGUUAUAUCGAA) were transfected into HeLa cells using the 
DharmaFECT 4 Transfection Reagent (Dharmacon, T-2001-02) according to 
the manufacturer’s protocol. Briefly, cells were first seeded in DMEM full 
medium without antibiotics in a 6-well plate overnight. Prepare the siRNA 
solutions as follows: 20 μM siRNA (10 μL) was diluted with 1 × siRNA 
buffer for 10 times (for the siRNA buffer, diluted 5× siRNA stock solutions 
with dd H2O), then shake at RT for 30 min. After that, added 100 μL double 
free DMEM (penicillin and streptomycin free and FBS free) to mix with 
siRNA solution. At the same time, added 4 μL transfection reagent into 196 
μL double free DMEM. After 5 min, mixed the siRNA and diluted 
transfection reagent together followed by incubation at room temperature for 
20 min to allow the formation of transfection complexes. Lastly, Add the 
above 400 μL into the 6 well plate (with 1600 μL PS free medium. After 48 h, 
the cells were performed for the designated treatment.  
For plasmid transfection, HeLa cells were first seeded in 6-well plate with 
a confluency of 90% overnight. The control pcDNA or FTH-Flag plasmid 
were transfected into the cells using LipofectamineTM 2000 according to the 
manufacturer’s protocol. Briefly, 2 μg DNA (in 200 μL double free DMEM) 
was mixed with 8μL LipofectamineTM 2000 (in 200 μL double DMEM). After 
24 h, the cells were performed for the designated treatment.  
 
2.14. MEASUREMENT OF ROS PRODUCTION 
CM-H2DCFDA (Life technologies, C6827) and MitoSOXTM Red (MSR, 
Life technologies, M36008) were chosen for the detection of intracellular ROS 
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and mitochondrial superoxide production respectively. When CM-H2DCFDA 
passively diffuses into cells, its acetate groups are cleaved by intracellular 
esterases and subsequently oxidized by ROS and yield a fluorescent adduct, 
CM-DCF (Aon et al., 2003). MSR is a fluoroprobe for detection of superoxide 
in the mitochondria of live cells (Mukhopadhyay et al., 2007). Briefly, cells 
were first cultured in Lab-TekTM Chambered Coverglass or 24-well plate 
overnight. After the designated treatments, cells were incubated with 5 μM 
MSR o r 1 μM CM-H2DCFDA in PBS for 10 min. Then the MSR or CM-
H2DCFDA was removed and the cells were washed with PBS twice. The cells 
in the Coverglass were incubated in full medium and observed under a 
confocal microscopy. The cells in the 24-well plate were collected and 
fluorescence intensity was measured. We recorded the fluorescence of CM-
DCF using FL-1 channel and MSR with FL-2 channel of FACS (BD 
Biosciences).  
 
2.15. LUCIFERASE ASSAYS 
TFEB luciferase vector was provided by Dr. A Ballabio (Sardiello et al., 
2009). The transient transfection of TFEB luciferase vector was done in HeLa 
cells using LipofectamineTM 2000 transfection reagent. Renilla luciferase 
vector was used as a transfection control. The luciferase activity was measured 
at 48 h after transfection using a Dual-Luciferase Reporter Assay System 
(Promega, Madison, WI, E1960) based on the protocol provides by the 
manufacturer. Briefly, each well was added with cell lysis reagent for about 15 
min followed by designated treatments. Then the cell lysate was collected and 
added into 96-well plate. After the addition of luciferase assay substrate, the 
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firefly luciferase activity was determined by a luminometer (Promega) and the 
Renilla luciferase activity was then measured by adding the Stop & Glo 
substrate. 
 
2.16. REVERSE TRANSCRIPTION AND QUANTITATIVE REAL-TIME PCR 
RNA was extracted with the RNeasy kit (Qiagen, Venlo, Limburg, 
217004). The concentration as well as the quality of the extracted RNA was 
determined by NanoDrop 1000 Spectrophotometer (Thermo Scientific). A 
reverse transcription reaction was performed using 1 μg of total RNA with 
iScript™ Reverse Transcription Supermix for qRT-PCR (Bio-Rad, 170-8841). 
The mRNA expression levels were determined by real-time PCR using 
SsoFast EvaGreen Supermix (Bio-Rad, 172-5201AP) and CFX96 Touch Real-
time PCR Detection System (Bio-Rad). Glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) was used as an internal control of RNA integrity. 
Real time PCR was performed in triplicates. The primers used for FTH and 
FTL were purchased from Qiagen: Hs_FTH1_1_SG QuantiTect Primer Assay 
(QT00072681) and Hs_FTL_1_SG QuantiTect Primer Assay (QT00055860). 
 
2.17. STATISTICAL ANALYSIS 
All western data and image data presented are representatives from three 
independent experiments. The numeric data except qRT-PCR data are 
presented as means ± S.D. from three independent experiments and analyzed 
using student t-test. qRT-PCR data are presented as mean ± SD from two 










CHAPTER 3.  






ART, a water soluble derivative of artemisinin, has been widely used for 
treatment of malaria (Anderson et al., 2012). Autophagy or macroautophagy 
refers to an evolutionarily conserved process in which cellular proteins and 
organelles are engulfed into autophagosomes, and then delivered to lysosomes 
for degradation (Meijer and Codogno, 2009). 
At present, the effects of ART on autophagy remain controversial. It has 
been reported that ART inhibits autophagy via inhibition of lysosomal 
turnover without affecting lysosomal functions in breast cancer cells 
(Hamacher-Brady et al., 2011). In contrast, one recent report showed that ART 
promotes autophagy via up-regulation of the expression of Beclin 1, which 
was also studied in breast cancer cells (Rogov et al., 2014). In addition, three 
other separate studies showed that dihydroartmisinin (DHA), another 
derivative of artemisinin, was able to induce autophagy (Du et al., 2013; Hu et 
al., 2013; Wang et al., 2012). Therefore, we want to test the effect of ART on 
autophagy in HeLa and HepG2 cells. 
At the maturation/degradation stage of autophagy, autophagosomes fuse 
with lysosomes to form autolysosomes for degradation (Mizushima and 
Komatsu, 2011; Settembre et al., 2013). During autophagic process induced by 
amino acid starvation or mTORC1 inhibitors, there is an increase of lysosomal 
function (Zhou et al., 2013b). The molecular mechanism of lysosomal 
biogenesis, activation, reformation and turnover has been summarized in a 
recent review (Shen and Mizushima, 2014). However, the effect of ART on 
lysosomal function has not been systematically studied. There is only one 
report suggesting that ART has no obvious effect of ART lysosomal function 
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(Hamacher-Brady et al., 2011). In our study, we will utilize different 
approaches to investigate the effect of ART on lysosomal function.  
In this part, we demonstrated ART induces autophagy via inhibition 
mTORC1 activity and enhancing lysosomal function. We showed strong 
evidence indicating ART induces lysosomal activation via enhancing V-
ATPase V1 and V0 subunit assembly.  
 
3.2. RESULTS 
3.2.1 ART induces autophagy  
We first used HeLa cells with stable expression of GFP-LC3 protein. LC3 
the homologue of Atg8 in yeast, is thought to be engaged in the expansion of 
autophagosomal membranes (Nakatogawa et al., 2007). The lipidated and 
membrane-bound LC3-II is considered as an indicator for autophagosome 
(Kabeya et al., 2000). As shown in Figure 3.1A-3.1B, ART markedly 
increased the average area of GFP-LC3 puncta and changed their distribution 
pattern (clustered to the perinuclear region), which is consistent with the 
earlier finding (Hamacher-Brady et al., 2011). Because the increase of 
autophagosome number may be caused either by the increased autophagosome 
formation and/or blocked autophagic maturation and degradation (Mizushima 
et al., 2010). Therefore, we performed “autophagic flux” assay to check the 
effect of ART on autophagy. We did a combined treatment of ART with 
vinblastine, a microtubule depolymerizing agent which inhibits the maturation 
of autophagic vacuoles (Punnonen and Reunanen, 1990). As shown in Figure 
3.1A-3.1D, the presence of vinblastine significantly increased the autophagic 
markers (both GFP-LC3 puncta and LC3-II protein level), indicating that ART 
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increases autophagic flux in HeLa cells.  
 
 
Figure 3.1 ART induces autophagy.  
A. HeLa cells with stable expression of GFP-LC3 were treated with 50 µM 
ART or combined with vinblastine (1μM) for 16 h. Autophagosomes were 
inferred by the presence of GFP-LC3 puncta under confocal microscopy. 
Scale bar, 10 μm. B. Stable GFP-LC3 HeLa cells were treated as in (A), 
fluorescence images were taken using confocal microscope and the area of 
GFP-LC3 puncta was quantified using ImageJ. Data (mean ± SD) are 
representative of three independent experiments. (*p < 0.05, Student’s t-test). 
C. HeLa cells were treated as in panel (A), western blot was then performed 
for the detection of LC3-II abundance. D. The band density of LC3-II protein 
was quantified using Imagequant TL (GE Healthcare Life Sciences). Data 
(mean ± SD) are representative of three independent experiments. (*p < 0.05, 




3.2.2 ART inhibits mTORC1 activity via the PI3K-Akt-TSC pathway 
MTORC1 signaling has been well established as the key negative 
regulator of autophagic process (Chang et al., 2009; Jung et al., 2010). Under 
nutrient-sufficient condition or at the absence of mTORC1 inhibitors, higher 
mTORC1 activity is able to suppress the ULK1 activity via direct 
phosphorylation of ULK1, which leads to the inhibition of autophagosome 
formation (Jung et al., 2009; Kim et al., 2011). Therefore, we next studied the 
role of mTORC1 in ART-induced autophagy. We first performed a time-
course treatment of ART in HeLa and HepG2 cells and then measured the 
phosphorylation level of ribosomal protein S6. S6 is a substrate of S6 kinase 1 
(S6K1) and S6K1 is a direct substrate of mTORC1 (Laplante and Sabatini, 
2012). Therefore, the phosphorylation level of S6 or S6K is usually used as an 
indicator of mTORC1 activity. As shown in Figure 3.2A, mTORC1 activity 
was decreased as evidenced by the loss of S6 protein phosphorylation with 
prolonged treatment of ART (after 12 h) in HeLa cells. The same trend was 
also observed in HepG2 cells (Figure 3.2B). We also checked the dose effect 
of ART and we found that higher dose of ART inhibits the phosphorylation of 
S6 most efficiently (Figure 3.2C). All together, the data indicated ART 







Figure 3.2 ART inhibits mTORC1 in a time- and dose- dependent 
manner.  
A. HeLa cells were treated with 50 µM ART as indicated time point. Western blot 
was then performed for the detection of S6 protein phosphorylation. B. HepG2 cells 
were treated as in (A) and checked with western blot. C. HeLa cells were treated with 





As mentioned in Chapter 1 (Introduction), there are mainly 3 pathways, 
controlling mTORC1 activity: the amino acid-Rag GTPase pathway (Sancak 
et al., 2010; Zoncu et al., 2011a), the class I PI3K-Akt-TSC pathway (Inoki et 
al., 2002; Manning et al., 2002; Potter et al., 2002), and the AMPK pathway. 
Earlier studies have shown ART inhibit PI3K-Akt-TSC pathway (Cheng et al., 
2011). Therefore, we first utilized Tsc2+/+ and Tsc2-/- MEFs to investigate the 
involvement of PI3K-Akt-TSC pathway in mTORC1 inhibition. As shown in 
Figure 3.3A, we observed a higher phosphorylation level of S6 in Tsc2-/- 
MEFs. This higher phosphorylation level of S6 is due to the constitutive 
mTORC1 activity in Tsc2-/- cells (Ng et al., 2011). However, ART failed to 
inhibit the phosphorylation of S6 in Tsc2-/- MEFs, indicating that ART inhibits 
mTORC1 via the PI3K-Akt-TSC pathway. To further confirm the finding, we 
then treated the cells with choloroquine (CQ), bafilomycin A1 (BAF), two 
lysosomal inhibitors, which has been shown to inhibit mTORC1 due to the 
induction of lysosomal stress (Settembre et al., 2012). As shown in Figure 
3.3B, both CQ and BAF showed inhibitory effect on the phosphorylation of S6 
in both Tsc2+/+ and Tsc2-/- MEFs. Taken together, ART is inhibits mTORC1 
via inhibiting PI3K-Akt-TSC pathway. Because the minimal saturation effect 
of CQ on HeLa cells is 40 μM (Ni et al., 2011), lowest concentration of CQ 
(10 μM) failed to inhibit the mTORC1 in Tsc2-/- MEFs (Figure 3.3B). 
We also checked the effect of ART on AMPK and there is no significant 
effect of ART on the phorsphorylation of AMPK (Figure 3.2A-3.2B), 









Figure 3.3 ART inhibits mTORC1 via inhibition PI3K-Akt-TSC 
pathway. 
A. Tsc2+/+ MEFs and Tsc2-/- MEFs were treated with ART (50 μM) for the 
indicated period of time and immunoblotted for the indicated markers. B. 
Tsc2+/+ MEFs and Tsc2-/- MEFs were treated with CQ (indicated dose), BAF 
and ART (50 μM) for the indicated period of time and immunoblotted for the 





3.2.3 Accumulation of ART in the lysosomes is independent of lysosomal 
pH 
3.2.3.1 ART accumulates in the lysosomes 
Lysosomes play a key role in autophagic process and an earlier study has 
indicated that functional lysosomes are required for ART-induced cell death 
(Hamacher-Brady et al., 2011). We then tried to look into the effect of ART 
on lysosomal function. We first utilized LynxTag-ARTTM ASBlue, a blue 
fluorescent-tagged ART to investigate its intracellular localization. As shown 
in Figure 3.4A, ART was found to be predominantly localized in the 
lysosomes, evidenced by its co-staining with LysoTracker Red (LTR). We 
also stained the mitochondria with MitoTracker Red (MTR) and the result 
showed that there was little colocalization of ART with MTR (Figure 3.4B), 








Figure 3.4 ART accumulates in the lysosomes.  
A. HeLa cells were treated with blue fluorescent ART (20 μM) for 30 min, 
following by LTR incubation. B. HeLa cells were treated with blue fluorescent 
ART for 30 min and then incubated with MTR. All images were analyzed 





3.2.3.2 Accumulation of ART in the lysosomes is independent of lysosomal pH 
To test whether the localization of ART in the lysosomes is due to the low 
pH of lysosomes, we performed a combined treatment with lysosome V-
ATPase inhibitor BAF. Notably, treatment with BAF abolished LTR staining 
of the lysosomes (Figure 3.5A). However, there is still an accumulation of 
ART. To investigate whether this accumulation of ART under combined 
treatment with BAF is still localized in the lysosomes, immunofluorenscence 
staining of lysosomal-associated membrane protein 1 (LAMP1) was then 
utilized to indicate the lysosomes. As shown in Figure 3.5B, there is a 
colocalization of ART with LAMP1, which is consistent with the LTR finding 
(Figure 3.4A). As expect, BAF treatment showed no effect on the ART 
lysosomal accumulation (Figure 3.5B), suggesting that ART accumulation in 








Figure 3.5 Accumulation of ART in the lysosomes is independent of 
lysosomal pH. 
A. HeLa cells were first treated with blue fluorescent ART (20 μM) combined 
with BAF (50 nM) for 30 min, following by LTR incubation for 30 mins. B. 
HeLa cells were treated with ART alone or combined with BAF for 1 h and 
then immunostained with LAMP1 (red). All images were analyzed using 




3.2.4 ART activates lysosomal function 
Next, we investigated the effects of ART on lysosomal function 
determined by the following assays: (i) lysosomal pH indicated by LTR and 
LysoTracker Green (LTG), (ii) cathepsin enzyme activities measured by 
Magic Red fluorescence intensity with both confocal microscopy and flow 
cytometry, and (iii) lysosomal proteolysis capability using the DQ Red BSA 
reagent.  
 
3.2.4.1 ART decreases lysosomal pH 
LTR and LTG are fluorophores containing a weak basic amine that 
selectively accumulates in acidic compartments (Freundt et al., 2007). The 
fluorescence intensity increases when lysosomal function increases during 
autophagic process or decreases when lysosome pH increases by lysosomal 
inhibitors (Zhou et al., 2013b). As shown in Figure 3.6A-3.7A, ART treatment 
enhanced LTR and LTG staining significantly, suggesting that ART treatment 
decreases lysosomal pH. We also performed a time-course-analysis and the 
fluorescence intensity of LTR was quantified by flow cytometry. As shown in 
Figure 3.6B, there is a time-dependent increase of the LTR staining, indicating 
that the decrease of lysosomal pH is in a time-dependent manner. The similar 









Figure 3.6 ART decreases lysosomal pH.  
A. HeLa cells were first treated with ART (50 μM) for 12 h followed by LTR 
labeling for 30 min and further analyzed using confocal microscopy. B. HeLa 
cells were loaded with LTR following time course drug treatment and 
fluorescence intensity was measured by flow cytometry. C. HepG2 cells were 





3.2.4.2 ART increases lysosomal enzymatic activity. 
Cathepsins are lysosomal cysteine proteases which play an important role 
in physiological and pathophysiological processes (Creasy et al., 2007; Turk et 
al., 2001). Magic Red™ Cathepsin assays are based on the cresyl violet (CV) 
fluorogenic substrate. The CV is bi-substituted with specific cathepsin peptide 
sequences. When the substrates are cleaved by cathepsins, the peptide is then 
released and the fluorophore becomes fluorescent (Boonacker and Van 
Noorden, 2001; Creasy et al., 2007). Here we utilized Magic Red Cathepin B 
and L to measure the lysosomal cathepsin B and L enzymatic activity. As 
shown in Figure 3.7A, ART increased the Magic Red cathepsin L fluorescence 
intensity when observed under the confocal microscopy. We also quantified 
the fluorescence intensity with flow cytometry and ART significantly 
increased both the Magic Red cathepsin B and L fluorescence intensity 
(Figure 3.7B). The data thus indicates that ART is able to enhance the 
enzymatic activity in HeLa cells. Similar results were also observed in HepG2 





Figure 3.7 ART increases lysosomal cathepsin B and L activity. 
A. HeLa cells were treated with ART for 12 h and then incubated with Magic 
Red cathepsin L and LysoTracker Green (LTG) for 30 min and observed 
under a confocal microscope. B. HeLa cells were treated as in (A) followed by 
Magic Red cathepsin B and L assay. Fluorescence intensity of 10, 000 cells 
per sample was measured using flow cytometry. C. HepG2 cells were treated 




3.2.4.3 ART increases lysosomal proteolysis. 
Finally, we utilized DQ Red BSA to detect the lysosomal proteolytic 
activity. DQ Red BSA is a kind of fluorophore with a red BODIPY dye 
conjugated to bovine serum albumin (BSA). It is easily self-quenched and 
hydrolysis of this compound leads to its dequenching (Vazquez and Colombo, 
2009). As shown in Figure 3.8, there is an increase of DQ Red BSA intensity 
in ART treated cells, and the DQ Red BSA was also shown to be co-localized 
with LTG, suggesting that ART promotes the lysosomal proteolysis. The 
similar results were also found in amino acid free medium, which serves as a 
positive control. Lysosomal inhibitor BAF abolished both DQ Red BSA 
staining and LTG staining. Taken together, ART promotes lysosmal 
proteolysis.  
In summary, the data above showed that ART promotes lysosomal 
function via decreasing lysosomal pH, increasing cathepsin activity and 









Figure 3.8 ART promotes lysosomal protein proteolysis. 
HeLa cells were first loaded with DQ Red BSA for 1 h, then treated with ART 
(50 μM)/BAF for 18 h or amino acid free medium for 3 h followed by 




3.2.5 ART treatment does not increase lysosomal number 
To check whether the increase of the above staining is due to the increase 
of lysosome number, we examined the changes of LAMP1 protein level 
treated with ART. We first performed immunofluorescence staining of 
LAMP1 and the result showed that there was a cluster of lysosomes in ART-
treated cells (Figure 3.9A), which is consistent with the earlier study 
(Hamacher-Brady et al., 2011). We then performed statistical analysis of the 
LAMP1 signal and there was no significant difference between the control 
group and ART-treated cells (Figure 3.9B). To further confirm our findings, 
we then checked temporal pattern of LAMP1 and there was no increase of 
LAMP1 protein level in ART-treated cells for up to 18 h (Figure 3.9C), 









Figure 3.9 ART treatment does not increase lysosomal number.  
A. HeLa cells were treated with ART for 18 h and then immunostained for 
LAMP1. B. LAMP1 signals of 80 cells from three independent experiments 
were quantified by ImageJ (#, no significance, student’s t-test). C. HeLa cells 
were treated with ART for the indicated time and then western blot was 




3.2.6 Mechanisms of lysosomal activation by ART 
3.2.6.1 Activation of lysosomal function by ART is independent of mTORC1 
and autophagy  
Earlier studies from our lab have shown that mTORC1, the negative 
upstream regulator of autophagy, inhibits lysosomal function in the course of 
autophagy (Zhou et al., 2013b). We have shown that mTORC1 activity can be 
inhibited by ART (Figure 3.2-3.3). Therefore, there is a possibility that ART 
promotes lysosomal function via inhibiting mTORC1 activity. However, 
evident lysosomal activation was found from 3 h onwards in ART-treated cells 
(Figure 3.6B) while the inhibitory effect of ART on mTORC1 only occurs 
after longer time point (12 h afterwards). In other words, the mTORC1 
suppression observed in ART-treated cells occurs later than lysosomal 
activation, thus excluding that possibility that lysosomal activation is due to 
the mTOR inhibition. To further confirm this finding, we utilized Tsc2+/+ and 
Tsc2-/- MEFs. In Tsc2-/- MEFs, ART failed to inhibit the phosphorylation of S6 
(Figure 3.3A-3.3B) while it was still capable of increasing cathepsin B and 
cathepsin L enzymatic activity (Figure 3.10A), suggesting that mTORC1 
inhibition may not play a role in ART-mediated lysosomal activation. Similar 











Figure 3.10 ART increases lysosomal function independent of mTORC1.  
Tsc2+/+ MEFs and Tsc2-/- MEFs were treated with ART (50 μM) for 24 h and 
then incubated with Magic Red cathepsin B and L for 30 min. The 
fluorescence intensity was analyzed using flow cytometry. B. TSC2 wild type 
(TSC loc) and knockdown (TSC2 shRNA) HeLa cells were treated as 
indicated for 24 h. C TSC2 wild type (TSC loc) and knockdown (TSC2 






3.2.6.2 ART promotes lysosomal function independent of autophagy 
To understand the role of autophagy in ART-mediated lysosomal 
activation and cell death, we performed siRNA knockdown of ATG7, one of 
the key autophagy-related genes (ATGs) in mediating autophagosome 
formation (Komatsu et al., 2005). As shown in Figure 3.11A, knockdown of 
ATG7 abolished LC3-II formation and ART-induced autophagy. However, 
knockdown of ATG7 failed to have any evident effect on lysosomal enzymatic 
activity in ART-treated HeLa cells (Figure 3.11B), indicating that lysosomal 








Figure 3.11 ART increases lysosomal function independent of 
Autophagy. 
A. HeLa cells were transfected with ATG7 siRNA or scrambled siRNA for 48 
h. B. After 48 h of siRNA transfection, HeLa cells were treated with ART for 
24 h, followed by cathepsin B and L enzymatic activities determined using 




3.2.6.3 ART promotes lysosomal function independent of TFEB 
It has been reported that transcription factor EB (TFEB) plays a critical 
role in the biogenesis of lysosomes (Sardiello et al., 2009). We next looked 
into the role of TFEB in the course of lysosomal activation. ART increased the 
TFEB transcriptional activity in HeLa cells as indicated by the increase of 
luciferase activity at 24 h (Figure 3.12A). However, knockdown of TFEB did 
not affect lysosomal activation induced by ART (Figure 3.12B-3.12C), 
suggesting that TFEB is not directly involved in the activation of lysosomal 








Figure 3.12 ART increases lysosomal function indepedent of TFEB.  
A. HeLa cells were transiently transfected with a TFEB luciferase report 
vector together with Renilla luciferase vector as a transfection control. Cells 
were then treated with ART (50 μM) as indicated for a time-course assay. B. 
HeLa cells were transiently transfected with TFEB siRNA or scrambled 
siRNA as control for 48 h. C. After transiently transfected with TFEB siRNA 
or scrambled siRNA for 48 h, HeLa cells were treated with ART for 24 h and 
then incubated with Magic Red Cathepsin B. Fluorescence intensity was 




3.2.6.4 ART promotes lysosomal function via increasing V-ATPase V1 subunit 
and V0 subunit assembly. 
We next investigated the role of lysosomal Vacuolar (H+)-ATPase (V-
ATPase) in the lysosomal activation induced by ART. V-ATPase is required 
for the acidification of lysosomes and it is activated when the peripheral V1 
and integral V0 domains assemble into a single complex on the lysosomes 
membrane (Mindell, 2012). We therefore examined the assembly status of the 
V1 and V0 domain in ART treated cells. As shown in Figure 3.13A, there was 
an increase of subunit B2 of V1 domain accumulation on the lysosomes in 
ART treated group detected by immunofluorescence staining. In order to 
confirm such findings, we performed the Proximity Ligation Assay (PLA). 
The use of two different PLA probes with amplifiable DNA reporter enables 
us to visualize and quantify the protein-protein interactions in situ (Tak and 
Firestein, 2001). The data clearly showed an increased proximity between 
V1B2 and V0D1 upon ART treatment (Figure 3.13B). All together, the data 
from this part suggest that ART is able to enhance lysosomal function via 





Figure 3.13 ART increases lysosomal function via increasing V-ATPase 
assembly.  
A. HeLa cells were treated with ART for 12 h, and then coimmunostained for 
V-ATPase B2 (green) and LAMP1 (red). Scale bar, 10 μm. B. HeLa cells were 
treated as in (D) and then PLA assay was performed for the detection of 













CHAPTER 4.  
FERRITIN DEGRADATION IS REQUIRED FOR ART-INDUCED 






ART together with other derivatives of artemisinin were first shown to 
exist toxicity to Ehrlich ascites tumor cells (Eisenstein, 2000). At present, 
there is increasing amount of evidence suggesting that ART has anti-cancer 
function (Krishna et al., 2004). For instance, ART has been shown to induce 
apoptosis and necrosis in multiple human cancer cells (Du et al., 2010; Zhou 
et al., 2012). The anti-cancer effects of ART also include the followings: cell 
cycle arrest (Zhao et al., 2011), inhibition of angiogenesis (Dell'Eva et al., 
2004), and reduction of cell invasion and metastasis (Rasheed et al., 2010). 
Moreover, the anti-cancer potential of ART has also been tested in a number 
of animal cancer models (Du et al., 2010; Hou et al., 2008b; Zhao et al., 2011). 
However, the exact mechanisms underlying ART-mediated cell death have not 
been fully elucidated. 
Iron is an essential nutrient and its intracellular availability is tightly 
regulated. One of the key regulatory mechanisms involves ferritin (Rouault, 
2006). Ferritin functions as the major iron storage protein in mammals and 
consists of 24 protein subunits that can store up to 4,500 atoms of iron per 
ferritin (Ford et al., 1984). There are two subunits of ferritin, ferritin heavy 
chain (FTH) and ferritin light chain (FTL). FTH has a ferroxidase function 
that can catalyze extra cellular iron into nontoxic ferric iron form and store 
this form of iron in the ferritin complex (Harrison and Arosio, 1996). Ferritin 
is stable in iron-rich conditions whereas it is rapidly degraded under 
conditions of iron starvation (Asano et al., 2011). Ferritin has been reported to 
be degraded either in the lysosomes or by the proteasomes depending on the 
cellular stimulants (De Domenico et al., 2009). Up to date, the effect of ART 
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on ferritin and the link between free iron ions and lysosomal function in ART-
induced cell death has not been well studied. 
Recently, the nuclear receptor coactivator 4 (NCOA4) was identified as 
the cargo for the ferritin degradation via autophagic pathway and the 
autophagic turnover of ferritin is termed as ferritinophagy (Bellelli et al., 
2014). Earlier studies have shown that ART-induced cancer cell death is 
dependent on lysosomes, while the mechanism is unclear (Hamacher-Brady et 
al., 2011). 
In this chapter, we aimed to elucidate the underlying molecular 
mechanisms of how lysosome involves in ART-induced cell death. We first 
confirmed that ART induces apoptosis in cancer cells. We then showed that 
ART promotes ferritin degradation in the lysosomes and we also provide clear 
evidence demonstrating that ferritin degradation via lysosomes is essential for 
ART-induced cell death. The results from our study shed new light on the 
molecular mechanisms underlying ART-induced cell death and support the 






4.2.1 ART inhibits cell proliferation and induces cell death in human 
cancer cells 
ART has been shown to inhibit cell growth, induce the radiosensitivity 
and enhance TRAIL-induced apoptosis in human cervical cancer HeLa cells 
(Lee et al., 2012; Luo et al., 2014; Thanaketpaisarn et al., 2011). However, the 
cell death effect of ART treatment alone in HeLa cells has not been well 
studied. We first treated the cells with ART (50 µM, 24 h) and the cell 
proliferation was inhibited as evidenced by the reduced cell number (Figure 
4.1A). We then examined the cytotoxicity of ART on HeLa cells and we 
found that ART (50 µM, 48 h) caused evident cell death in HeLa cells, as 
assessed by morphological changes (Figure 4.1B, upper panel), Hoechst 
staining for chromatin condensation (Figure 4.1B, lower panel) and 
quantitatively through PI-live cell exclusion test (Figure 4.1C-4.1D). 
Moreover, ART-induced cell death was also found to be time- and dose-














Figure 4.1 ART inhibits cell proliferation and induces cell death in 
cancer cells.  
A. HeLa cells were treated with ART (50 μM) for 24 h and then observed 
under a light microscopy. B. HeLa cells were treated with ART (50 μM) for 
48 h Morphological changes of ART-induced cell death was observed under a 
light microscopy (upper panel) or by using a fluorescent microscopy after 
incubation with Hoechst dye for 30 min (lower panel). Scale bar, 200 μm. C. 
HeLa cells were treated as indicated time point and the cell death was 
quantified by flow cytometry using propidium iodide (PI, 5 µg/ml) staining 
(R1 area, a representative of viable cells). D. HeLa cells were treated with 
indicated dose of ART and cell death was quantified by flow cytometry after 




4.2.2 ART induces apoptotic cell death in human cancer cells 
To further examine the type of cell death induced by ART, we first 
checked the classical markers of apoptotic cell death in HeLa cells treated with 
ART. As shown in Figure 4.2A, we observed a cleavage of both caspase-3 (17 
kDa) and PARP (89 kDa). We next tested the protective effect of a general 
caspase inhibitor, N-benzyloxycarbonyl-Phe-Ala-fluoromethylketone (Z-
VAD), on ART-mediated cell death. As shown in Figure 4.2B, the cell death 
induced by ART was dramatically protected by Z-VAD. As expected, the 
caspase-3 and PARP cleavage can also be blocked by Z-VAD (Figure 4.2C). 
Because earlier studies have demonstrated the inhibitory effect of Z-VAD on 
cathespins (Schotte et al., 1999; Wu et al., 2008), we then tested whether the 
Z-VAD is able to inhibit cathepsin activity in our model. As shown in Figure 
4.2D, Z-VAD treatment showed no effect on the cathepsin B and L activity 
either alone or combined treatment with ART, suggesting that the inhibition of 
cell death is due to its caspase inhibition effect. Interestingly, we also observed 
that Z-VAD cannot fully block ART-induced cell death, indicating that there 
is still some other form of cell death included. Similar results were also 




Figure 4.2 ART induces apoptosis in HeLa cells.  
A. HeLa cells were collected after treatment with ART (50 μM) for the 
indicated period of time, western blot was then performed for the detection of 
various indicated markers of apoptosis. β-actin and tubulin served as loading 
controls. B. HeLa cells were treated with ART (50 μM) with or without Z-
VAD (20 μM) for 48 h. Cell death was quantified using PI exclusion assay 
coupled with flow cytometry. C. HeLa cells were treated with ART (50 μM) 
alone or combined with Z-VAD (20 μM) together for 24 h followed by 
western blotting to detect the apoptosis markers. D. HeLa cells were treated as 
in (C) and then incubated with Magic Red cathepsin B/L for 30 min. The 







Figure 4.3 ART induces apoptosis in HepG2 cells.  
A. HepG2 cells were treated with ART (50 μM) with or without Z-VAD (20 
μM) for 48 h and then observed under a light microsocopy. B. HepG2 cells 
were treated as in (A) and the cell death was quantified using PI exclusion 
assay coupled with flow cytometry.  
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4.2.3 ART induces oxidative stress  
It has been reported that ART is able to increase intracellular reactive 
oxygen species (ROS) level as an important cell death mechanism (Mercer et 
al., 2011). We first used CM-H2DCFDA to measure the intracellular ROS. 
ART treatment increased the intracellular ROS production evidenced by the 
increased CM-DCF fluorescence intensity (Figure 4.4A), indicating that ART 
treatment increases ROS production. Addition of antioxidant N-acetylcysteine 
(NAC), which has been shown to directly react with hydrogen peroxide and 
superoxide (Winterbourn and Metodiewa, 1999), was able to inhibit the 
production of intracellular ROS induced by ART (Figure 4.4A). Since 
mitochondria are the main site of ROS formation and superoxide is the 
precursor of most other ROS such as hydrogen peroxide (Turrens, 2003), we 
next utilized MitoSOX Red (MSR) to detect the superoxide production in 
mitochondria. As shown in Figure 4.4B, ART treatment significantly 
increased mitochondrial ROS level. Addition of NAC partially prevented 
ART-mediated mitochondrial ROS production (Figure 4.4B). We also tested 
the protective effect of NAC on ART-induced cell death and we observed that 






Figure 4.4 ART increase intracellular ROS production.  
A. HeLa cells were treated with ART with or without NAC for 24 h followed 
by incubation with CM-H2DCFDA. The fluorescence intensity was analyzed 
by flow cytometry. B. HeLa cells were treated as in (A) followed by 
incubation with MSR. The fluorescence intensity was analyzed by flow 
cytometry. C. HeLa cells were treated with ART with or without NAC for 48 
h and the cell death were quantified by PI exclusion assay couple with flow 
cytometry. D. Statistical analysis of three independent experiments as in (C).  
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4.2.4 Lysosomes functions as the upstream of mitochondrial ROS 
production 
The two lysosomal inhibitors BAF and CQ have been shown to inhibit 
intracellular ROS production (Hamacher-Brady et al., 2011). We next tested 
whether BAF and CQ are able to inhibit mitochondrial ROS production. As 
shown in Figure 4.5A-4.5C, production of mitochondrial ROS was almost 
completely abolished by BAF and CQ, indicating the possibility that lysosome 
functions as upstream of mitochondria in ROS production in ART-treated cells. 
To further confirm the involvement of lysosomes in cellular ROS production 
upon ART treatment, we examined the changes of lysosomal function using 
NAC or BAF. As shown in Figure 4.5D, BAF was able to completely inhibit 
ART-induced lysosomal activation, while NAC failed to have any effect, 
further confirming the earlier notion that lysosome acts as upstream of 
mitochondrial ROS production. Taken together, these data indicate that 
lysosomes function as upstream of mitochondria in ROS production in ART-
treated cells. As expected, both BAF and CQ significantly protected ART-














Figure 4.5 Mitochondrial ROS production induced by ART can be 
inhibited by lysosomal inhibitor.  
A. HeLa cells were treated with ART with or without BAF (50 nM) for 24 h 
followed by incubation with LTG in full DMEM for 30 min and then MSR in 
PBS for 15 min. The cells were then observed under a confocal microscopy. 
Scale bar, 10 μm. B. HeLa cells were treated with ART with or without CQ 
(50 μM) for 24 h and then incubated with MSR as indicated earlier. C. Cells 
were treated as indicated as in (A) and (B) followed by incubation with MSR. 
Fluorescence intensity of MSR was recorded by flow cytometry. D. HeLa 
cells were treated with ART with or without BAF as indicated for 12 h. Magic 







Figure 4.6 Cell death induced by ART can be inhibited by lysosomal 
inhibitors.  
HeLa cells were treated with ART with or without BAF (50 nM) or CQ (20 
μM) for 48 h. The cells were observed under light microscopy (A). The cell 
viability was quantified using PI exclusion assay coupled with cytometry (B). 
Data (mean ± SD) are representative of three independent experiments (C). 





4.2.5 Lysosomal activation, ROS production and cell death induced by 
ART is dependent on lysosomal iron 
Since ferrous iron is essential for the activity of ART (Lai et al., 2013; 
Mercer et al., 2011), and lysosomes are known to be containing high 
concentration of ferrous iron (Terman and Kurz, 2013), we then utilized 
deferoxamine mesylate (DFO), a lysosomal iron chelator to investigate the 
role of lysosomal iron in ART-induced cell death. DFO is known as a 
lysosomal iron chelator because of its poor membrane permeability and thus it 
enters into cells through endocytosis and mostly localizes to lysosomes (Cable 
and Lloyd, 1999; Kurz et al., 2004; Lloyd et al., 1991). Here, we first observed 
that mitochondrial ROS production induced by ART was inhibited by DFO 
(Figure 4.7A). Consistently, the increased intracellular ROS level by ART 
treatment can also be reduced by DFO (Figure 4.7B). Consequently, DFO was 
shown to completely block ART-induced cell death (Figure 4.7C-4.7D), which 
is consistent with the earlier finding (Hamacher-Brady et al., 2011).  
We then test the effect of DFO on lysosomal function and we found that 
DFO inhibited ART-induced lysosomal activation, evidenced by the 
followings: (i) inhibition of lysosomal acidification induced by ART (Figure 
4.8A), (ii) blockage of ART-mediated lysosomal enzymatic activation (Figure 
4.8B), and (iii) suppression of ART-enhanced lysosomal proteolysis (Figure 
4.8C). In summary, these data indicate that lysosomal iron plays a critical role 





Figure 4.7 ROS production as well as cell death induced by ART can 
be inhibited by lysosomal iron chelator.  
A. HeLa cells were treated with ART with or without DFO for 24 h. 
Mitochondrial ROS was measured by MSR as indicated earlier. B. HeLa cells 
were treated as in (A). Intracellular ROS was measured by H2DCFDA as 
indicated earlier. C. HeLa cells were treated with ART for 48 h. The cell 
viability was quantified using PI exclusion assay coupled with cytometry (B). 
D. Data (mean ± SD) are representative of three independent experiments (C). 





Figure 4.8 Chelating of lysosome iron is able to inhibit the lysosome 
activation induced by ART.  
A. HeLa cells were treated with 50 μM ART alone or combined with DFO 
(100 μM) for 16 h. Lysosomal pH was indicated by LTR fluorescence 
intensity. B. HeLa cells were treated as indicated in (A). Magic Red cathepsin 
B and L activities were determined as indicated earlier. C. HeLa cells were 
first loaded with DQ Red BSA for 1 h and then treated as indicated in (A). The 





4.2.6 ART promotes ferritin degradation in the lysosomes 
Iron level within lysosomes is high because lysosomes release the iron 
from transferrin or degrade iron-containing proteins such as ferritin in the 
acidic environment (Terman and Kurz, 2013). Ferritin is the major iron 
storage protein in cells (Ford et al., 1984) , and it has been shown to be 
degraded in the lysosomes under iron-depleted conditions in cancer cells 
(Asano et al., 2011). Since our results showed that ART accumulates in the 
lysosomes and activates lysosomal function (Figure 3.4 – Figure 3.8), we then 
hypothesized that ART may promote ferritin degradation. To test this 
hypothesis, we first examined the changes of both FTH and FTL degradation 
in cells treated with ART. We observed a time- and dose-dependent reduction 
of their protein level (Figure 4.9A-4.9B). To check whether the decreased 
ferritin protein level is due to the enhanced protein degradation, we first 
measured the mRNA level of ferritin. As shown in Figure 4.9C-4.9D, there 
was a time-dependent increase of both FTH and FTL mRNA level in ART-
treated cells, suggesting that the reduced ferritin protein level by ART is 
unlikely via suppression of transcription.  
Next, to investigate whether the ferritin degradation induced by ART is 
performed by lysosomes, we inhibited the lysosomal function by lysosomal 
inhibitors BAF and CQ. As shown in Figure 4.9E, ART-reduced ferritin 
protein level was completely blocked by BAF and CQ. In contrast, proteasome 
inhibitor MG132 cannot fully inhibit ferritin degradation induced by ART. 
These results thus indicate that ART-induced ferritin degradation is mainly 
performed by lysosomes. We also observed that DFO treatment was able to 
reduce the ferritin protein level (Figure 4.10A), which is consistent with the 
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earlier reports (Asano et al., 2011). Although we observed a decrease of 
ferritin mRNA level in DFO-treated cells (Figure 4.10B-4.10C), reduction of 
mRNA level (after 6 h) occurred later than that of protein (from 3 h onwards) 
(Figure 4.10A). Consistently, DFO-induced ferritin degradation can also be 
inhibited by BAF (Figure 4.10D), indicating that DFO is also able to promote 













Figure 4.9 ART promotes ferritin degradation in the lysosomes.  
A. HeLa cells were treated with 50 µM ART as indicated time point. Western 
blot was then performed for the detection of FTH and FTL abundance. B. 
HeLa cells were treated with ART as indicated dose for 24 h. C.D. HeLa cells 
were treated with 50 µM ART as indicated time point, the FTH (C) and FTL 
(D) mRNA levels were measured by RT-qPCR. (*P < 0.05, **P < 0.01 
Student’ s t-test). E. HeLa cells were treated with BAF (50 nM), DFO (100 






Figure 4.10 DFO promote ferritin degradation in the lysosomes.  
A. HeLa cells were treated with 100 µM DFO as indicated time point. Western 
blot was then performed for detection of FTH and FTL abundance. B. C. 
HeLa cells were treated with 100 µM DFO as indicated time point, the FTH 
(B) and FTL (C). D. HeLa cells were pre-treated with DFO for 2 h and then 
incubated with 50 nM BAF for 6 h. Western blot was then performed for 




4.2.7 Overexpression of FTH reduces ART-induced cell death  
Because both BAF and CQ were found to inhibit ferritin degradation 
(Figure 4.9E) and protected ART-induced cell death (Figure 4.6), we thus 
hypothesized that BAF or CQ inhibits ART-induced cell death via inhibiting 
the ferritin degradation and subsequently suppresses the iron release from 
ferritin. Therefore, to further investigate the role of ferritin degradation in 
ART-induced cell death, we over-expressed flag-tagged FTH, which has been 
shown to decrease cytosolic iron level and to increase the resistance to 
oxidative stress (Cozzi et al., 2000). As shown in Figure 4.11A, there was no 
reduction of Flag-FTH protein level in ART treated cells. And over-expression 
of FTH significantly protected ART-induced cell death, especially in higher 
concentration of ART-treated cells (Figure 4.11B-4.11C), suggesting that 







Figure 4.11 Overexpression FTH rescues the cell death induced by ART. 
A. HeLa cells were transiently transfected with pcDNA or Flag-tagged FTH 
plasmid (Flag-FTH) for 48 h followed by ART (50 µM) treatment for 24 h. B. 
HeLa cells were transiently transfected with Flag-FTH for 48 h and then 
treated with ART for 48 h. The cell viability was quantified by flow cytometry 
after PI staining. C. Statistical significanceof data from panel B was indicated 




4.2.8 Autophagy plays a marginal role in ART-induced cell death  
Our data showed that lysosomes play an important role in ferritin 
degradation and it is also a critical component in autophagic process as 
mentioned earlier. In addition, it has been shown that autophagy plays a role in 
ferritin degradation in iron-deficient MEFs and HeLa cells (Asano et al., 2011). 
We next examined the role of autophagy in ART-mediated ferritin degradation. 
As shown in Figure 4.12A, knockdown of ATG7 failed to inhibit ferritin 
degradation. Also, we tested the toxicity effect of ART on ATG7 knockdown 
cells and there is a slightly increase of cell viability (Figure 4.12B), indicating 









Figure 4.12 Autophagy does not play a major role in ART-induced cell 
death.  
A. HeLa cells were transiently transfected with scrambled siRNA or ATG7 
siRNA for 48 h. B. HeLa cells were transiently transfected with scrambled 




4.2.9 Lysosomal delivery and degradation of ferritin is required for 
ART-induced cell death 
Although ferritin has been reported degraded in the lysosomes as we 
mentioned earlier, the exact pathway of how ferrtin goes into lysosome for 
degradation is unclear until one recent report identified NCOA4 as a specific 
cargo receptor mediating the delivery and degradation of ferritin in lysosomes 
(Mancias et al., 2014). Therefore, to further confirm our earlier notion that 
ferritin degradation is required for ART-induced cell death, we used RNAi to 
knockdown NCOA4 and then checked ART-induced cell death. As shown in 
Figure 4.13A, knockdown of NCOA4 blocked ferritin degradation (both heavy 
chain and light chain). As expected, knockdown of NCOA4 offered significant 
protect against ART-induced cell death in HeLa cells (Fig. 4.13B). All 
together, these data suggest that it is not the lysosomes per se required for 
ART-induced cell death but delivery and degradation of ferritin in lysosomes 




Figure 4.13 Cell death induced by ART can be inhibited by NCOA4 
knockdown.  
A. HeLa cells were transiently transfected with scrambled siRNA or NCOA4 
siRNA for 48 h. B. HeLa cells were transiently transfected with scrambled 
siRNA and NCOA4 siRNA for 48 h and then treated with ART for 48 h. The 
cell viability was quantified by flow cytometry using PI live cell exclusion 
staining. C. Statistical significance of data from panel B was indicated in the 











CHAPTER 5.  




5.1. THE EFFECT OF ART ON AUTOPHAGY  
The effect of ART on autophagy was first reported by Hamacher-Brady et 
al (Hamacher-Brady et al., 2011). They found that ART inhibits autophagy via 
disrupting endolysosomal trafficking. In their study, they showed that (i) ART 
induces perinuclear clustering of autophagosomes, early and late endosomes, 
and lysosomes; (ii) lysosomal iron is upstream of mitochondrial outer 
membrane permeabilization; (iii) lysosomal inhibitors are able to inhibit ART-
induced cell death. We also found the similar results (Figure 3.1A, Figure 4.7 
and Figure 4.6). However, we found that ART is able to induce autophagy, 
based on the observations that ART increased autophagosomes formation and 
enhanced autophagic flux (Figure 3.1). We also demonstrate that ART induces 
autophagy via a dual mechanism: suppression of mTORC1 activity (Figure 3.2) 
and activation of lysosomal function (Figure 3.6-3.8). With regards to the 
discrepancy, it is believed that, in addition to the different contexts of the 
experiments (cell type, culture medium, etc), another possibility is due to the 
difference in data interpretation. For example, the clustered autophagosomes, 
early and late endosomes, as well as lysosomes in response to ART were 
interpreted as evidence for the inhibitory effect of ART on autophagy 
(Hamacher-Brady et al., 2011). However, it has been shown that during 
starvation-mediated autophagy, there is a perinuclear clustering of lysosomes 
driven by changes of intracellular pH (Korolchuk et al., 2011). Therefore, we 
believe that this perinuclear clustering of lysosomes is in fact, an indication of 
autophagy induction. Indeed, one recent report showed that ART induces 
autophagy via upregulation of Beclin 1 expression (Rogov et al., 2014). 
Moreover, our findings are consistent with three other reports suggesting that 
120 
 
DHA was able to induce autophagy in cancer cells (Du et al., 2013; Hu et al., 
2013; Wang et al., 2012). DHA is a derivative of artemisinin, with a similar 
mechanistic action as ART (Eckstein-Ludwig et al., 2003; Zhang and Gerhard, 
2009). Therefore, it is reasonable to postulate that ART might have the similar 
effect on autophagy as DHA. 
In our study, we identified two possible mechanisms underlying ART-
induced autophagy. First, we found that ART was able to inhibit mTORC1 
activity (Figure 3.2). It has been well established that mTORC1 is the key 
negative regulator of autophagy via suppressing the ULK1 complex consisting 
of ULK1, FIP200 and ATG13 (Hosokawa et al., 2009). The inhibitory effect 
of ART on mTORC1 is consistent with an earlier report that ART inhibited 
the PI3K/Akt signaling pathway (Cheng et al., 2011). The PI3K-Akt-Tsc 
signaling pathway is a positive regulator of mTORC1 activity and thus 
inhibition of PI3K/Akt will lead to the inhibition of mTORC1 (Zoncu et al., 
2011b). Second, we provided strong evidence that ART promotes lysosomal 
function (Figure 3.6-3.8). As functional lysosomes are essential for the 
maturation stage of autophagy, activation of lysosomal function will lead to an 
increase in the turnover of the autolysosomes and autophagic flux (Zhou et al., 
2013b). Although mTORC1 has been shown to inhibit lysosomal 
function(Zhou et al., 2013b), we found that the lysosomal activation mediated 
by ART is independent of mTORC1 (Figure 3.10). Taken together, our study 
demonstrates that ART induces autophagy via a dual mechanism: suppression 




5.2. THE EFFECT OF ART ON LYSOSOMES 
One of the novel findings from our study is the activation of lysosomal 
functions by ART, based on two main observations. First, ART accumulates in 
the lysosomes (Figure 3.4) and second, ART increases lysosomal acidification, 
cathepsin enzyme activity and protein degradation via promoting lysosomal 
V-ATPase assembly (Figure 3.13). Accumulation of ART in lysosomes is 
indeed consistent with the findings in malaria parasite, in which artemisinin 
was found to be accumulated in the parasite’s digestive food vacuole (Pandey 
et al., 1999). Although one earlier study showed that acridine-based 
fluorescent-labelled artemisinin did not localize into the parasite food vacuole 
(Eckstein-Ludwig et al., 2003), it was later found that this inconsistency was 
due to the quenching of fluorescence of this acridine-based fluorophores in the 
acidic food vacuole (Stocks et al., 2007).  
In an attempt to understand the underlying mechanisms of ART-mediated 
lysosomal activation, we investigated the possible role of lysosomal V-
ATPase and found that assembly status of V1 domain and V0 domain of V-
ATPase was increased by ART treatment (Fig. 3.13). The V-ATPase complex 
contains two domains: peripheral V1 domain and integral V0 domain. The V1 
domain consists of eight different subunits (A-H) and is responsible for ATP 
hydrolysis; while the V0 domain, composed of six subunits, drives proton from 
cytoplasm to the lumen (Cipriano et al., 2008; Nishi and Forgac, 2002). Based 
on the reversible association model, V-ATPase is active when the two 
domains assemble into a single complex on the lysosomes membrane (Li and 
Kane, 2009; Mindell, 2012). Therefore, ART may increase lysosomal V-
ATPase activity via promoting the assembly status of the two domains. 
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Apparently, our data differ from an earlier report in which ART did not affect 
lysosomal pH and cathepsin B activity (Hamacher-Brady et al., 2011). One 
possibility underlying the discrepancy between these two studies is the 
different cell culture conditions used: in our study, cells were treated with 
ART in full medium (high glucose DMEM medium with 10% FBS), while 
Hamacher-Brady et al treated cells in Krebs-Henseleit solution (KHS), a 
defined glucose containing basic salt solution (Hamacher-Brady et al., 2011). 
Since lysosomal function is known to be up-regulated in the course of 
autophagy (Efferth et al., 2008; Zhou et al., 2013b), it is likely that lysosomal 
activity was increased when the cells were cultured in KHS solution, thus 
making it hard to detect the further activation of lysosomal function by ART 
under this context. However, the exact mechanism for the lysosomal 
accumulation by ART is still not known which needs to be further investigated.  
 
5.3. THE IMPORTANCE OF ROS IN ART-INDUCED CELL DEATH 
It has been well established that oxidative stress-ROS is the major cause 
of ART-induced cell death (Cheng et al., 2013; Efferth et al., 2007; Mercer et 
al., 2011). Several mechanisms have been proposed for ART-induced 
oxidative stress. On one hand, it has been showed that the mitochondrial 
electron transport chain is involved in ROS generation induced by ART 
(Mercer et al., 2011). On the other hand, ART was able to inhibit the 
expression and activities of antioxidants superoxide dismutase in ovalbumin-
challenged mice (Ho et al., 2012). In our study, we observed that increase of 
mitochondrial ROS (measured by MSR) occurred at an earlier time point (6 h), 
prior to ART-induced cell death (after 18 h) (data not shown). In addition, the 
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antioxidant NAC reduced ROS level and showed protective effect on ART-
induced cell death (Figure 4.4). All these observations support the notion that 
oxidative stress contributes to cell death. As discussed earlier, the 
endoperoxide bridge of ART is broken by ferrous iron and then ART becomes 
free radicals to target cellular organelles such as mitochondria and eventually 
leads to cell death (Mercer et al., 2007). Consistent with earlier findings 
(Hamacher-Brady et al., 2011), we also found that DFO, the lysosomal iron 
chelator, was able to reduce ROS level and cell death (Figure 4.7), implicating 
that lysosomal iron is a critical mediator in ART-induced mitochondrial ROS 
production and cell death. Since iron released from ferritin degradation inside 
the lysosome can be utilized by the cells (Asano et al., 2011), it is thus 
possible that enhanced lysosomal degradation of ferritin induced by ART 
leads to the transient increase of cytosolic ferrous iron, which then affects the 
mitochondria, leading to enhanced mitochondrial ROS production.  
 
5.4. THE ROLE OF IRON IN ART-INDUCED LYSOSOMAL ACTIVATION 
In addition to the critical role in the ROS production, we also found that 
lysosomal iron functions as upstream of lysosomal activation, which may be 
caused by the iron-related bioactivity of ART. At present, the chelating effect 
of DFO on lysosomal iron has been well established, partly based on the two 
well-cited papers (Cable and Lloyd, 1999; Lloyd et al., 1991). In addition, it is 
also known that DFO enters cells by endocytosis and mostly localizes to 
lysosomal compartment by another group (Kurz et al., 2004; Ollinger and 
Brunk, 1995). On the other hand, it is known that the labile iron is mainly 
localized in the acid organelles such as lysosomes, while only a small 
124 
 
proportion of iron presents in cytoplasm (Kurz et al., 2004). Third, the iron in 
the cell culture medium is ferric iron at a concentration of 10-17M (Klausner et 
al., 1993), which is rather negligible comparing to the iron level in mammalian 
cells (0.2-1.5 µM) (Epsztejn et al., 1997). As for the inhibitory effect of DFO 
on lysosomal function, we believe that DFO removes the labile iron, leading to 
reduction of ART reaction with iron and its activation, subsequently indirectly 
blocks the activation of lysosomal function induced by ART.  
We also observed BAF and CQ effectively inhibit cell death induced by 
ART (Figure 4.6). At present, the effect of BAF on the iron release from 
lysosome is inconclusive. On the one hand, BAF treatment attenuates iron 
release from lysosomes in MEFs via inhibition the degradation of ferrtin 
(Asano et al., 2011). On the other hand, it has been reported that BAF 
treatment promotes the release of iron from lysosomes in hepatocytes 
(Uchiyama et al., 2008). Moreover, such a mechanism has attributed to the 
fact that BAF is capable of enhancing the cytotoxicity of phthalocyanine 4-
PDT (Photodynamic therapy) in A431 cancer cells and in human head and 
neck squamous carcinoma cells via increased mitochondrial iron uptake (Hung 
et al., 2013; Saggu et al., 2012). As a specific inhibitor of the lysosomal V-
ATPase, BAF the lysosomal/endosomal pH gradients is collapsed instantly by 
the treatment (Gagliardi et al., 1999). Although BAF depletes lysosomal iron 
may leads to reduced ART reaction with lysosomal iron and thus subsequently 
protect against ART-mediated cell death, we still believe that the protective 
effect of BAF against ART-mediated cell death is achieved via blockage of 
ferritin degradation and subsequent iron release based on the following 
reasons: in Uchiyama et al.’s study, they showed that iron releases from 
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lysosomes with BAF treatment occurs within 2 hours, much slower than the 
collapse of lysosomal pH gradient. They also believed that iron release from 
lysosomes is cause by the collapse of lysosomal/endosomal pH gradients. 
Since our study showed that BAF inhibits ART-induced cell death even at 48 
h. In the long term, we believe that the protective of BAF is caused by the 
abolished lysosomal acidification which leads to the inhibition of ferritin 
degradation, subsequently, attenuates the iron release from lysosome and 
reduces the cytotoxicity.  
 
5.5. THE ROLE OF LYSOSOME FERRITIN AND AUTOPHAGY IN ART-
INDUCED LYSOSOMAL ACTIVATION AND CELL DEATH 
To understand the involvement of lysosomes in iron-related bioactivity of 
ART, we examined the changes of ferritin including both FTH and FTL. On 
one hand, ferritin protein can be regulated at the post-transcriptional level, in 
which IRP binds with ferritin 5’- IRE to repress its translation under iron-
depleted conditions (Rouault, 2006). On the other hand, there is evidence 
showing that DFO induces ferritin degradation through the lysosome pathway 
(Asano et al., 2011; De Domenico et al., 2009; Kidane et al., 2006). In this 
study, we observed that BAF completely blocked ART and DFO-mediated 
FTH and FTL degradation (Figure 4.9E and Figure 4.10D), suggesting that 
ART or DFO-mediated reduction of ferritin protein level is mainly via 
lysosome-dependent degradation. Notably, although DFO induces ferritin 
degradation, the released iron from ferritin degradation is effectively chelated 
by DFO, leading to the protective effect of DFO on ART-induced cell death.  
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However, one intriguing finding is that over-expression of FTH cannot 
completely prevent ART-induced cell death (Figure 4.11). One possibility is 
that although FTH homopolymers are functional in sequestering iron, it is less 
efficient than the H/L heteropolymer, based on an earlier report that FTH 
over-expression only led to a 50% reduction of labile iron pool (chelatable and 
redox active iron) in HeLa cells (Cozzi et al., 2000). Therefore, there is still a 
proportion of labile iron for the toxicity of ART. In addition, in cells with FTH 
overexpression, iron still can be released from FTL degradation, which will 
activate ART and cause its cytotoxicity.  
As we have discussed earlier, functional lysosomes has been shown be 
required for ART-induced cell death although the mechanism is unknown 
(Hamacher-Brady et al., 2011). Our study unveiled that ferritin degradation in 
the lysosomes play an important role in ART-induced cell death, based on the 
following observations: (i) ART activated lysosomal functions and promotes 
ferritin degradation; and (ii) BAF and CQ, two lysosomal inhibitors were able 
to effectively ferritin degradation and thus inhibit the cell death induced by 
ART. In addition, ART showed little toxicity effect on NCOA4 knockdown 
cells, further confirming our notion that ferritin delivery and degradation in 
lysosomes is required for the toxicity of ART. Interestingly, we observed 
reduced cell viability in NCOA4 knockdown cells (Figure 4.13), indicating the 
importance of ferritin delivery and degradation in lysosomes in maintaining 
cell viability. 
Interestingly, we also found that the protective effect of autophagy via 
Atg7 knockdown is marginal although it is statistically significant (Figure 
4.12B). Indeed, the minor protective effect is consistent with the data that 
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ART promotes lysosomal function and ferritin degradation independent of 
autophagy (Figure 3.11 and Figure 4.12A).  
 
5.6. CONCLUSIONS 
In this study, we have investigated the mechanisms of ART-induced 
cancer cells by focusing on autophagy and lysosomes. The whole study 
consists of 2 parts. In the first part of the study, we have tried to examine the 
effect of ART on autophagy and explore the underlying mechanisms The 
major findings from the first part of the study are (i) ART induces autophagy 
(ii) ART suppresses mTORC1 activity via PI3K/Atk pathway; (iii) ART 
promotes lysosomal function via enhancing V-ATPase V1 and V0 subunit 
assembly. In the second part of the study, we have attempted to investigate the 
role of lysosome in ART-induced cell death and its underlying mechanisms. 
The major findings from the second part of the study are (i) ART induces 
lysosome-dependent cell death; (ii) Lysosomal iron functions as the upstream 
of ROS production as well as lysosomal activation; (iii) Activated lysosomal 
function by ART enhances ferritin degradation in the lysosomes; (iii) The 
delivery of ferritin for lysosomal degradation is required for ART-induced cell 
death.  
In summary, we demonstrate a novel mechanism underlying ART-
induced cancer cell death. As shown in Figure 5.1, ART accumulates in 
lysosomes and reacts with lysosomal iron. The activated ART then promotes 
autophagy via enhancing lysosomal function and inhibiting mTORC1 acitivity. 
One major source of iron for the cytotoxicity of ART is attained from the 
degradation of ferritin by lysosomes, which requires the adaptor protein 
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NCOA4 for the delivery. At present, there is evidence demonstrating higher 
iron levels in cancer cells than non-cancerous cells, and iron has been targeted 
for cancer therapy and prevention (Torti and Torti, 2013).Therefore, the 
results from our study support the development of this important anti-malaria 
drug as a cancer therapeutic agent. 
 
 
Figure 5.1 Illustration showing the mode of action by ART on 
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